<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Psychopharmacology (Berl)</journal-id>
<journal-id journal-id-type="iso-abbrev">Psychopharmacology (Berl.)</journal-id>
<journal-title-group>
<journal-title>Psychopharmacology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0033-3158</issn>
<issn pub-type="epub">1432-2072</issn>
<publisher>
<publisher-name>Springer Berlin Heidelberg</publisher-name>
<publisher-loc>Berlin/Heidelberg</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">26983414</article-id>
<article-id pub-id-type="pmc">4869740</article-id>
<article-id pub-id-type="publisher-id">4265</article-id>
<article-id pub-id-type="doi">10.1007/s00213-016-4265-2</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Investigation</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>A mouse model of the 15q13.3 microdeletion syndrome shows prefrontal neurophysiological dysfunctions and attentional impairment</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Nilsson</surname>
<given-names>Simon R. O.</given-names>
</name>
<address>
<phone>+1 (203) 444 6821</phone>
<email>sn440@cam.ac.uk</email>
</address>
<xref ref-type="aff" rid="Aff1"></xref>
<xref ref-type="aff" rid="Aff2"></xref>
<xref ref-type="aff" rid="Aff3"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Celada</surname>
<given-names>Pau</given-names>
</name>
<xref ref-type="aff" rid="Aff4"></xref>
<xref ref-type="aff" rid="Aff5"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fejgin</surname>
<given-names>Kim</given-names>
</name>
<xref ref-type="aff" rid="Aff6"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Thelin</surname>
<given-names>Jonas</given-names>
</name>
<xref ref-type="aff" rid="Aff6"></xref>
<xref ref-type="aff" rid="Aff7"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Nielsen</surname>
<given-names>Jacob</given-names>
</name>
<xref ref-type="aff" rid="Aff6"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Santana</surname>
<given-names>Noemí</given-names>
</name>
<xref ref-type="aff" rid="Aff4"></xref>
<xref ref-type="aff" rid="Aff5"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Heath</surname>
<given-names>Christopher J.</given-names>
</name>
<xref ref-type="aff" rid="Aff1"></xref>
<xref ref-type="aff" rid="Aff2"></xref>
<xref ref-type="aff" rid="Aff8"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Larsen</surname>
<given-names>Peter H.</given-names>
</name>
<xref ref-type="aff" rid="Aff6"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Nielsen</surname>
<given-names>Vibeke</given-names>
</name>
<xref ref-type="aff" rid="Aff6"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kent</surname>
<given-names>Brianne A.</given-names>
</name>
<xref ref-type="aff" rid="Aff1"></xref>
<xref ref-type="aff" rid="Aff2"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Saksida</surname>
<given-names>Lisa M.</given-names>
</name>
<xref ref-type="aff" rid="Aff1"></xref>
<xref ref-type="aff" rid="Aff2"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Stensbøl</surname>
<given-names>Tine B.</given-names>
</name>
<xref ref-type="aff" rid="Aff6"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Robbins</surname>
<given-names>Trevor W.</given-names>
</name>
<xref ref-type="aff" rid="Aff1"></xref>
<xref ref-type="aff" rid="Aff2"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bastlund</surname>
<given-names>Jesper F.</given-names>
</name>
<xref ref-type="aff" rid="Aff6"></xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Bussey</surname>
<given-names>Timothy J.</given-names>
</name>
<xref ref-type="aff" rid="Aff1"></xref>
<xref ref-type="aff" rid="Aff2"></xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Artigas</surname>
<given-names>Francesc</given-names>
</name>
<xref ref-type="aff" rid="Aff4"></xref>
<xref ref-type="aff" rid="Aff5"></xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Didriksen</surname>
<given-names>Michael</given-names>
</name>
<xref ref-type="aff" rid="Aff6"></xref>
</contrib>
<aff id="Aff1"><label></label>Department of Psychology, University of Cambridge, Cambridge, CB2 3EB UK </aff>
<aff id="Aff2"><label></label>MRC and Wellcome Trust Behavioural and Clinical Neuroscience Institute, University of Cambridge, Cambridge, CB2 3EB UK </aff>
<aff id="Aff3"><label></label>Department of Psychology, State University of New York at Binghamton, Binghamton, NY 13902-6000 USA </aff>
<aff id="Aff4"><label></label>Institut d’Investigacions Biomèdiques de Barcelona, CSIC-IDIBAPS, Barcelona, Spain </aff>
<aff id="Aff5"><label></label>Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain </aff>
<aff id="Aff6"><label></label>H. Lundbeck A/S, Synaptic Transmission, Neuroscience Research DK, Ottiliavej 9, Valby, 2500 Denmark </aff>
<aff id="Aff7"><label></label>Neuronano Research Center, Lund University, 223 81 Lund, Sweden </aff>
<aff id="Aff8"><label></label>Department of Life, Health and Chemical Sciences, The Open University, Walton Hall, Milton Keynes, MK7 6AA UK </aff>
</contrib-group>
<pub-date pub-type="epub">
<day>17</day>
<month>3</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>17</day>
<month>3</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="ppub">
<year>2016</year>
</pub-date>
<volume>233</volume>
<fpage>2151</fpage>
<lpage>2163</lpage>
<history>
<date date-type="received">
<day>6</day>
<month>1</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>25</day>
<month>2</month>
<year>2016</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2016</copyright-statement>
<license license-type="OpenAccess">
<license-p>
<bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p>
</license>
</permissions>
<abstract id="Abs1">
<sec>
<title>Rationale</title>
<p>A microdeletion at locus 15q13.3 is associated with high incidence rates of psychopathology, including schizophrenia. A mouse model of the 15q13.3 microdeletion syndrome has been generated (Df[h15q13]/+) with translational utility for modelling schizophrenia-like pathology. Among other deficits, schizophrenia is characterised by dysfunctions in prefrontal cortical (PFC) inhibitory circuitry and attention.</p>
</sec>
<sec>
<title>Objectives</title>
<p>The objective of this study is to assess PFC-dependent functioning in the Df(h15q13)/+ mouse using electrophysiological, pharmacological, and behavioural assays.</p>
</sec>
<sec>
<title>Method</title>
<p>Experiments 1–2 investigated baseline firing and auditory-evoked responses of PFC interneurons and pyramidal neurons. Experiment 3 measured pyramidal firing in response to intra-PFC GABA<sub>A</sub> receptor antagonism. Experiments 4–6 assessed PFC-dependent attentional functioning through the touchscreen 5-choice serial reaction time task (5-CSRTT). Experiments 7–12 assessed reversal learning, paired-associate learning, extinction learning, progressive ratio, trial-unique non-match to sample, and object recognition.</p>
</sec>
<sec>
<title>Results</title>
<p>In experiments 1–3, the Df(h15q13)/+ mouse showed reduced baseline firing rate of fast-spiking interneurons and in the ability of the GABA<sub>A</sub> receptor antagonist gabazine to increase the firing rate of pyramidal neurons. In assays of auditory-evoked responses, PFC interneurons in the Df(h15q13)/+ mouse had reduced detection amplitudes and increased detection latencies, while pyramidal neurons showed increased detection latencies. In experiments 4–6, the Df(h15q13)/+ mouse showed a stimulus duration-dependent decrease in percent accuracy in the 5-CSRTT. The impairment was insensitive to treatment with the partial α<sub>7</sub>nAChR agonist EVP-6124. The Df(h15q13)/+ mouse showed no cognitive impairments in experiments 7–12.</p>
</sec>
<sec>
<title>Conclusion</title>
<p>The Df(h15q13)/+ mouse has multiple dysfunctions converging on disrupted PFC processing as measured by several independent assays of inhibitory transmission and attentional function.</p>
</sec>
<sec>
<title>Electronic supplementary material</title>
<p>The online version of this article (doi:10.1007/s00213-016-4265-2) contains supplementary material, which is available to authorized users.</p>
</sec>
</abstract>
<kwd-group xml:lang="en">
<title>Keywords</title>
<kwd>Copy number variation</kwd>
<kwd>15q13.3</kwd>
<kwd>Animal model</kwd>
<kwd>
<italic>Chrna7</italic>
</kwd>
<kwd>Prefrontal cortex</kwd>
<kwd>Neurophysiology</kwd>
<kwd>Cognition</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>
<institution>Innovative Medicine Initiative n° 115008 </institution>
</funding-source>
<award-id>FP7/2007-2013</award-id>
</award-group>
</funding-group>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© Springer-Verlag Berlin Heidelberg 2016</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="Sec1" sec-type="introduction">
<title>Introduction</title>
<p>The 15q13.3 microdeletion syndrome (15q13.3DS) is caused by a rare (∼1:30000 births) (LePichon et al. <xref ref-type="bibr" rid="CR44">2010</xref>) copy number variant (CNV) with hemizygosity of at least seven genes on the long arm of chromosome 15. The microdeletion is associated with variable cognitive impairment and psychiatric or neurological disorders (Miller et al. <xref ref-type="bibr" rid="CR56">2009</xref>), including autism (Pagnamenta et al. <xref ref-type="bibr" rid="CR64">2009</xref>; Ben-Shachar et al. <xref ref-type="bibr" rid="CR11">2009</xref>), attention deficit hyperactivity disorder (Miller et al. <xref ref-type="bibr" rid="CR56">2009</xref>), obsessive compulsive disorder (Melchior et al. <xref ref-type="bibr" rid="CR54">2013</xref>), and epilepsy (Helbig et al. <xref ref-type="bibr" rid="CR33">2009</xref>). 15q13.3DS is also associated with a ∼10-fold increase in the risk of schizophrenia (International Schizophrenia Consortium <xref ref-type="bibr" rid="CR38">2008</xref>; Stefansson et al. <xref ref-type="bibr" rid="CR77">2014</xref>), making it one of the strongest known genetic risk factors for the disorder.</p>
<p>Among other alterations, the pathophysiology of schizophrenia is underpinned by imbalances within local prefrontal cortical (PFC) circuitry, typically observed as reductions in markers for cortical inhibitory signalling efficacy in histological (Lewis et al. <xref ref-type="bibr" rid="CR45">2005</xref>) and neurophysiological assays (Daskalakis et al. <xref ref-type="bibr" rid="CR17">2007</xref>; Javitt et al. <xref ref-type="bibr" rid="CR39">2008</xref>). Moreover, schizophrenia is characterised by core prefrontal-dependent “executive” cognitive impairments (Robbins <xref ref-type="bibr" rid="CR72">1990</xref>), perhaps most notably within the domain of attention (Carter and Barch <xref ref-type="bibr" rid="CR13">2007</xref>). Deficits in executive functioning have also been linked to dysregulated cortical recruitment and asynchronous activity partly produced by disrupted inhibitory activity during cognitive demand (Bickel and Javitt <xref ref-type="bibr" rid="CR12">2009</xref>; Nakazawa et al. <xref ref-type="bibr" rid="CR60">2012</xref>). Indeed, schizophrenia-related dysfunctions observed in measures of event-related neuronal responses are associated with attentional impairment (Nieman et al. <xref ref-type="bibr" rid="CR61">2002</xref>). The critical 15q13.3 segment also encompasses the <italic>CHRNA7</italic> gene, which is involved in cortical inhibitory transmission (Adams et al. <xref ref-type="bibr" rid="CR1">2012</xref>; Lin et al. <xref ref-type="bibr" rid="CR47">2014</xref>), regulates schizophrenia-relevant neurophysiological markers (Hajos et al. <xref ref-type="bibr" rid="CR31">2005</xref>), and is associated with attentional dysfunction (Adler et al. <xref ref-type="bibr" rid="CR3">1998</xref>; Young et al. <xref ref-type="bibr" rid="CR89">2004</xref>). The cognitive phenotypes associated with 15q13.3DS remain imprecisely defined and unspecific deficits typically ranging from moderate to mild intellectual disability have been described (Lowther et al. <xref ref-type="bibr" rid="CR51">2014</xref>; Gillentine and Schaaf <xref ref-type="bibr" rid="CR27">2015</xref>). The 15q13.3DS has also been associated with attentional impairments that can be independent of general intellectual functioning (Miller et al. <xref ref-type="bibr" rid="CR56">2009</xref>).</p>
<p>Preclinical lesion and local microinfusion studies have shown attentional functioning to be contingent on the activity in the medial prefrontal cortex (mPFC), including the prelimbic cortex (PrL) (Muir et al. <xref ref-type="bibr" rid="CR58">1996</xref>; Chudasama and Muir <xref ref-type="bibr" rid="CR14">2001</xref>; Passetti et al. <xref ref-type="bibr" rid="CR66">2002</xref>) and GABAergic activity in this area (Paine et al. <xref ref-type="bibr" rid="CR65">2011</xref>; Pehrson et al. <xref ref-type="bibr" rid="CR68">2013</xref>; Pezze et al. <xref ref-type="bibr" rid="CR69">2014</xref>). Recordings in animals during cognitive testing further indicate that inhibitory PrL-activity correlates with attentional performance in the 5-choice serial reaction time task (5-CSRTT) (Totah et al. <xref ref-type="bibr" rid="CR81">2009</xref>). We have previously generated a mouse model of the 15q13.3DS (Df[h15q13]/+) which shows 50 % reduction in messenger RNA (mRNA) expression of the genes in the region and several 15q13.3DS- and schizophrenia-like phenotypes, including decreases in the amplitude of cortical auditory-evoked potentials and aberrant responding to GABA<sub>A</sub> receptor (GABA<sub>A</sub>R) antagonism in seizure assays (Fejgin et al. <xref ref-type="bibr" rid="CR20">2014</xref>).</p>
<p>As part of the NEWMEDS initiative (Innovative Medicines Initiative Grant Agreement No. 115008), the current study tested the translational utility of the Df(h15q13)/+ mouse for schizophrenia-relevant cortical-dependent dysfunctions using multiple parallel experimental approaches. These approaches included measures of (i) pre-attentative processing through auditory-evoked neural responses, (ii) higher order executive attention through the touchscreen 5-CSRTT, and (iii) mechanistic processes through concurrent intra-PFC GABAergic pharmacology and measures of pyramidal neuron spontaneous discharge rates.</p>
</sec>
<sec id="Sec2" sec-type="materials|methods">
<title>Methods and materials</title>
<sec id="Sec3">
<title>Animals</title>
<p>The Df(h15q13)/+ mouse was generated by Taconic Artemis (Köln, Germany) as previously described (Fejgin et al. <xref ref-type="bibr" rid="CR20">2014</xref>). The Df(h15q13)/+ mice were of a c57BL/6NTac background. All experiments used male mice. Animals were housed under a 12-h light/dark cycle with stable temperature and humidity conditions with ad libitum access to food and water. Experiments 1–2 investigated baseline and auditory-evoked neural responses of putative pyramidal cells and interneurons and used 14 mice (age 10–14 weeks; wild type (WT) <italic>N</italic> = 7, Df(h15q13)/+ <italic>N</italic> = 7). Experiment 3 analysed pyramidal neuron responses to GABA<sub>A</sub>R antagonism and used 19 mice (age 10–14 weeks; WT <italic>N</italic> = 10, Df(h15q13)/+ <italic>N</italic> = 9). Experiments 4–12 assessed cognitive functions and used three cohorts of animals (each cohort: WT <italic>N</italic> = 16, Df(h15q13)/+ <italic>N</italic> = 16; age at start of testing: 10 weeks). Prior to cognitive testing, animals were food restricted and maintained at about 85 % of their free-feeding weight. Cohort 1 was tested on the 5-CSRTT (experiments 4–6) and novel object recognition (experiment 12). Cohort 2 was tested on visual discrimination and reversal learning (experiment 7), paired-associate learning (PAL) (experiment 8), trial-unique non-match to sample (TUNL) (experiments 11), and extinction learning (experiment 10). Cohort 3 was tested on progressive ratio (experiment 9). The experiments followed the European Union regulation (directive 2010/63 of 22 September 2010) and UK Animals (Scientific Procedures) Act 1986 and were approved by the Barcelona School of Medicine Institutional Animal Care and Use Committee and the Danish National Committee for Ethics in Animal Experimentation.</p>
</sec>
<sec id="Sec4">
<title>Experiments 1–2: cortical auditory-evoked neuronal firing</title>
<sec id="FPar1">
<title>Surgical procedures</title>
<p>Mice were anesthetised with Sevoflurane (Abbott Scandinavia AB, Solna, Sweden), and body temperature was maintained at 37 °C by an isothermal heating pad. A 16-channel array electrode (Innovative Neurophysiology, Durham, NC) was placed in the PrL at stereotaxic coordinates (from bregma and duramater) AP: +1.9 mm, L: +0.2 mm, and DV: -1.5 mm according to the mouse brain atlas (Paxinos and Franklin <xref ref-type="bibr" rid="CR67">2008</xref>) and secured through a set of skull-mounted anchor screws (over the cerebellum and contralateral to the prefrontal cortex electrode) and dental cement (3M relyX unicem self-adhesive universal resin cement). A small hole for ground wires was drilled adjacent to the cerebellum anchor screw. Mice were treated with a prophylactic antibiotic (5 mg/kg, s.c., Baytril vet®, 50 mg/ml Enrofloxacin, Bayer, Germany) and peripheral analgesic (1.5 mg/kg, s.c., Rimadyl vet®, 50 mg/ml Carprofen, Pfizer, USA) pre-surgery and for 5 days post-surgery. Mice were allowed ≥1 week of post-surgical recovery.</p>
</sec>
<sec id="FPar2">
<title>Signal acquisition</title>
<p>Activity of a large number of PrL neurons was recorded in freely behaving animals. Single- and multi-unit activities were recorded using a multichannel recording system (Plexon Inc. Dallas, TX). Continuously recorded data was band pass-filtered in order to avoid low frequency activity and visualise the action potentials. Frequencies below 300 Hz were filtered to delete the slow components of the raw data, and the upper cut-off frequency of 9000 Hz was applied to diminish the noisy appearance of the action potential shape (Quian Quiroga <xref ref-type="bibr" rid="CR71">2009</xref>). After filtering, action potentials were easily visualised on top of background noise activity and could be detected by using an amplitude threshold. Storage threshold for spiking events was three standard deviations of the peak height histogram of filtered signal. Artifact waveforms were removed, and the spike waveform minima were aligned using the Offline Sorter software (v3.2; Plexon, Dallas, TX).</p>
</sec>
<sec id="FPar3">
<title>Spike sorting and classification</title>
<p>Action potentials were sorted into unit clusters using the Offline Sorter software. Waveform features used for separating the units were the first three principal components of the sampled waveforms for a given dataset. A cluster was classified as a single unit when &lt;0.3 % of the spikes occurred within a 2-ms refractory period. To group units in putative cell types, we extracted two features from the average waveform: valley full width at half maximum and peak-to-valley time. The waveform features were plotted and used to classify the units as putative pyramidal cells or putative fast-spiking interneurons (Barthó et al. <xref ref-type="bibr" rid="CR8">2004</xref>) (see Supplementary Fig. <xref ref-type="media" rid="MOESM1">1</xref>a). Waveforms with a valley full width at half maximum duration &lt;0.35 ms and valley to peak time &lt;0.2 ms were considered interneurons, while waveforms with a half amplitude duration &gt;0.37 ms and valley to peak time &gt;0.15 ms were considered pyramidal cells. Waveforms not falling into one of the two groups were considered as intermediates and were not included for further analysis.</p>
</sec>
<sec id="FPar4">
<title>Auditory gating paradigm</title>
<p>Mice were tested in the dark phase and were habituated to the recording chamber for 40 min prior to the beginning of the session. Motor activity was manually monitored via an infrared camera, and recordings were made during resting state where periods with locomotor activity were excluded from analysis. Paired white noise auditory stimuli (white noise, 82 dB, 10 ms duration with 1 ms rise and fall, inter-stimulus interval 500 ms) were presented with an inter-pair interval of 10 s, and simultaneous recordings of single-unit activity were made for 10 min. A transistor-transistor logic (TTL) pulse 50 ms prior to the sound was used as event mark and saved together with single-unit data. Startle responses were not observed during the recording sessions. Peri-stimulus time histograms (PSTH) were constructed for each spike train with a bin width of 1 ms. The average PSTH across units were calculated after baseline subtraction (baseline interval: −1.4 to −0.4 s relative to first pulse) of each unit PSTH. The response amplitude was measured in a 30-ms bin starting 10 ms after the stimulus onset. The latency was set to the first 1 ms bin that was significantly higher than the baseline firing rate.</p>
</sec>
</sec>
<sec id="Sec5">
<title>Experiment 3: intra-mPFC GABA<sub>A</sub>R antagonism and pyramidal discharge rate</title>
<sec id="FPar5">
<title>Surgical procedures</title>
<p>Mice were anesthetised by acute dose of chloral hydrate (400 mg/kg i.p) and maintenance dose of ∼1 mg/kg/min i.p using a perfusion pump. A heating pad maintained body temperature at 37 °C. Single-unit recordings were performed using glass micropipettes pulled from 2-mm capillary glass (World Precision Instruments, Sarasota, FL) and a Narishige PE-2 pipette puller (Tokyo, Japan). Recorded signals were amplified (×10; Neurodata IR283 amplifier, Cygnus Technology Inc., Delaware Water Gap, PA), post-amplified and filtered (×100; band pass filter: 30 Hz–10 kHz) (Cibertec amplifier/filter, Madrid, Spain) and analysed using a DAT 1401plus interface system (Spike2, Cambridge Electronic Design, Cambridge, UK).</p>
</sec>
<sec id="FPar6">
<title>Intra-mPFC gabazine</title>
<p>Spontaneous discharge rates of putative pyramidal neurons in Df(h15q13)/+ and WT mice were analysed during control conditions and following local GABA<sub>A</sub>R antagonism as described in rat PFC (Lladó-Pelfort et al. <xref ref-type="bibr" rid="CR49">2012</xref>). Electrodes (impedances: 6–12 MΩ) containing saline 2 M or gabazine (20 mM, dissolved in 0.2 M NaCl; SR95531, Sigma-Aldrich, St Louis, MO) were placed at stereotaxic coordinates (from bregma) AP: +2.1 mm, L: −0.2–0.4 mm. Pyramidal neuron discharge was examined in the same mice in standard (NaCl) or gabazine conditions by performing track descents in both conditions. Electrode descents were made at DV: −1–2.5 mm (from duramater) according to the mouse brain atlas (Paxinos and Franklin <xref ref-type="bibr" rid="CR67">2008</xref>). Pyramidal neurons were identified by their electrophysiological characteristics: (i) duration of the depolarisation phase of the action potential (average of 10 spikes) and (ii) discharge rate (Lladó-Pelfort et al. <xref ref-type="bibr" rid="CR49">2012</xref>) (see Supplementary Fig. <xref ref-type="media" rid="MOESM1">1</xref>b). Gabazine was chosen due to its superior selectivity relative to the classical GABA<sub>A</sub>R antagonist bicuculline (Debarbieux et al. <xref ref-type="bibr" rid="CR18">1998</xref>; Stocker et al. <xref ref-type="bibr" rid="CR79">1999</xref>). Electrode tips (5–7-μm diameter) were broken to a final resistance of 9–15 MΩ. Gabazine reached recorded neurons through passive diffusion from the electrode as previously shown for bicuculline (Steward et al. <xref ref-type="bibr" rid="CR78">1990</xref>; Tepper et al. <xref ref-type="bibr" rid="CR80">1995</xref>). To obtain a reliable measure of spontaneous discharge rate, a 5-min recording was made for each putative pyramidal neuron after which the electrode was descended again.</p>
</sec>
</sec>
<sec id="Sec6">
<title>Experiments 4–6: the 5-choice serial reaction time task</title>
<sec id="FPar7">
<title>Apparatus</title>
<p>The 5-CSRTT experiments used 32 operant touchscreen chambers (Campden Instruments, Loughborough, UK) extensively described elsewhere (Horner et al. <xref ref-type="bibr" rid="CR36">2013</xref>; Mar et al. <xref ref-type="bibr" rid="CR52">2013</xref>).</p>
</sec>
<sec id="FPar8">
<title>5-choice serial reaction time task (5-CSRTT)</title>
<p>The 5-CSRTT is a rodent analogue of the human continuous performance task (CPT) measuring attention in which schizophrenic patients show impairments (Kahn et al. <xref ref-type="bibr" rid="CR40">2012</xref>). The 5-CSRTT is sensitive to mPFC lesions (Muir et al. <xref ref-type="bibr" rid="CR58">1996</xref>; Chudasama and Muir <xref ref-type="bibr" rid="CR14">2001</xref>; Passetti et al. <xref ref-type="bibr" rid="CR66">2002</xref>) and perturbations to mPFC inhibitory signalling in the rodent (Paine et al. <xref ref-type="bibr" rid="CR65">2011</xref>; Pehrson et al. <xref ref-type="bibr" rid="CR68">2013</xref>; Pezze et al. <xref ref-type="bibr" rid="CR69">2014</xref>) and impulsive and attentional impairments in mouse models of neuropsychiatric disorders (Young et al. <xref ref-type="bibr" rid="CR89">2004</xref>; Hoyle et al. <xref ref-type="bibr" rid="CR37">2006</xref>; Romberg et al. <xref ref-type="bibr" rid="CR74">2011</xref>). The task is described in extensive detail elsewhere (Mar et al. <xref ref-type="bibr" rid="CR52">2013</xref>). Briefly, animals were initially trained to respond to a white-square stimulus using a 2-s stimulus duration (SD), 40-trial session length, and 5-s delay. Once the animals had acquired the criterion of ≥80 % accuracy and ≤20 % for two consecutive sessions, they were tested on a series of probe tests. Each probe test lasted for two consecutive sessions, and the presented data represents the means for these 2 days (Romberg et al. <xref ref-type="bibr" rid="CR74">2011</xref>). These probe tests were always presented in order of increasing difficulty (i.e., SD probes were presented in order of decreasing durations, and delay probes were presented in order of increasing delays). During probe tests the animals were tested for 7 days a week. Between each probe test, the animals had to reacquire the criteria of ≥80 % accuracy and ≤20 % omissions for two consecutive sessions on the baseline task parameters of 2-s SD and 5-s delay. These baseline sessions were done in order to reduce potential proactive interference from previous probe tests (Romberg et al. <xref ref-type="bibr" rid="CR74">2011</xref>; Mar et al. <xref ref-type="bibr" rid="CR52">2013</xref>).</p>
<p>In experiment 4, the animals were initially tested on probe tests of increasing attentional demand by decreasing SDs (1.6, 1.0, 0.8, 0.6, 0.4, 0.2 s). Animals were then given tests of motor impulsivity by increasing delays (7, 9, 11, 13 s). Next, the animals were given tests of vigilance through increased session lengths (80 trials, followed by 140 trials). At each of these session lengths, the animals were tested on decreasing SDs (1.6, 1, 0.8, 0.6 s). In experiment 5, the test of 140 trials per session was repeated using 1.6, 1, 0.8, 0.6, 0.4, and 0.2 s SDs. Moreover, much recent focus has been on the therapeutic potentials of the partial α<sub>7</sub> nicotinic acetylcholine receptor (α<sub>7</sub>nAChR) agonist EVP-6124 against the cognitive deficits of schizophrenia (Garay et al. <xref ref-type="bibr" rid="CR26">2016</xref>). In experiment 6, animals were treated with EVP-6124 (Latin-square design; 0, 3, 10, 30 mg/kg, 10 ml/kg, 30 min pre-treatment time, i.p; EnVivo Pharmaceuticals) and tested again on the 140 trials, 0.8-s SD, and 5-s delay parameter. Each dose-phase was separated by 48 h. Animals were tested drug-free on the baseline parameters (140 trials, 2-s SD, 5-s delay) on sessions separating each dose-phase. Prior to commencing the Latin-square, animals were given two saline injections for habituation to the injection procedure.</p>
<p>The dependent variables were completed trials, percent accuracy (total number of correct trials divided by total number of correct and incorrect trials), percent omission (total number of omitted trials divided by the total number of trials), percent premature responses (total number of premature trials divided by the total number of trials), percent perseverative correct (total number of perseverative responses to the correct location divided by the total number of correct responses), and average response latency and average reward retrieval latency. Each session was also divided into 10-trial bins, and the dependent measures were calculated within each 10-trial bin.</p>
</sec>
</sec>
<sec id="Sec7">
<title>Experiments 7–12: additional cognitive assays</title>
<sec id="FPar9">
<title>Apparatus</title>
<p>The operant experiments used the same 32 touchscreen chambers that were used in experiments 4–6 (Campden Instruments, Loughborough, UK). The spontaneous object recognition experiment used two Y-shaped mazes made of Perspex.</p>
</sec>
<sec id="FPar10">
<title>Additional cognitive assays</title>
<p>Experiment 7 assessed discrimination learning and reversal learning in two separate two-choice challenges; the first using more discriminable stimuli and the second using more challenging stimuli (see Fig. <xref ref-type="fig" rid="Fig3">3a, b</xref>, inset). The task is described elsewhere (Mar et al. <xref ref-type="bibr" rid="CR52">2013</xref>). The dependent variables for reversal learning were trials to criterion, incorrect responses to criterion, correction trials to criterion, perseverative errors (the number of incorrect responses made before achieving &gt;50 % correct responding in session), learning errors (the number of incorrect responses made after achieving ≤50 % correct responses correct responding in a session), average response latency, and average reward retrieval latency.</p>
<p>Experiment 8 assessed paired-associate learning (PAL). The task is extensively described elsewhere (Horner et al. <xref ref-type="bibr" rid="CR36">2013</xref>). Animals were tested for 70 sessions, and the data was collapsed into 5-session bins for analyses. The main dependent variables were percent accuracy (expressed as the number of correct responses divided by the total number of correct and incorrect responses), correction trials, average response latency, and average reward retrieval latency.</p>
<p>Experiment 9 assessed touchscreen progressive ratio (PR) by employing linear ramp schedules of 4, 8, 12, and 16 touches. The task is extensively described elsewhere (Heath et al. <xref ref-type="bibr" rid="CR32">2015</xref>). The dependent variables were the total number of trials completed, breakpoint (defined as the number of screen responses emitted in the last successfully completed trial of the session), the total number of screen touches emitted during the session, and the number of “blank” location touches recorded during the session (corrected for total session time).</p>
<p>Experiment 10 assessed touchscreen extinction learning. The task is extensively described elsewhere (Mar et al. <xref ref-type="bibr" rid="CR52">2013</xref>). Within each session, the dependent variables were percent responses (the total number of responses divided by the number responses and omissions), the number of touchscreen responses during the ITI, and stimulus response latencies.</p>
<p>Experiment 11 used the touchscreen trial-unique non-match to sample (TUNL) task to assess working memory through increasing delays (2, 4, 6, and 8 s) followed by tests of decreasing stimuli separations to assess pattern separation (small, medium, large). The task is extensively described elsewhere (Oomen et al. <xref ref-type="bibr" rid="CR63">2013</xref>; Kim et al. <xref ref-type="bibr" rid="CR41">2015</xref>). The dependent variables were percent accuracy (total number of correct trials dived by the total number of correct and incorrect trials), percent correction trials (total number of correction trials dived by the total number of correct and incorrect trials), average response latency, and average reward retrieval latency.</p>
<p>Experiment 12 assessed novel object recognition using 8 h (trial 1) and 11 h (trial 2 and trial 3) delays. The tasks are extensively described elsewhere (Winters et al. <xref ref-type="bibr" rid="CR87">2008</xref>). Video analyses of behaviour were made by an experimenter blind to the genotype and location of the novel object using JWatcher (version 1.0). For each animal, the discrimination ratio was calculated (time spent exploring the novel object divided by the total time spent exploring the objects). Total object exploration times in the sample-phase and object-biases were also calculated.</p>
</sec>
</sec>
<sec id="Sec8">
<title>Data analyses and statistics</title>
<p>Analyses were done using SPSS (v21.0, IBM Corp, Armonk, NY). Auditory-evoked neural responses were analysed using one-way between-subjects ANOVAs. Gabazine effect on pyramidal neuron firing was analysed with two-way ANOVA (with treatment and genotype as main factors). The behavioural data was analysed with repeated measured ANOVAs. Significant interactions were followed by one-way ANOVAs or Newman-Keuls post hoc comparisons.</p>
</sec>
</sec>
<sec id="Sec9" sec-type="results">
<title>Results</title>
<sec id="Sec10">
<title>Experiment 1: baseline discharge rates</title>
<p>See Supplementary Figure <xref ref-type="media" rid="MOESM1">1</xref>a for waveform features used to classify units as putative pyramidal cells or putative fast-spiking interneurons. Df(h15q13/+) mice showed decreased baseline PrL interneuron discharge rate (Fig. <xref ref-type="fig" rid="Fig1">1a</xref>; <italic>F</italic><sub>1,94</sub> = 8.58, <italic>p</italic> = 0.004). There was no effect of genotype on baseline pyramidal neuron discharge rate (<italic>F</italic><sub>1,334</sub> = 1.71, <italic>p</italic> = 0.191).<fig id="Fig1"><label>Fig. 1</label><caption><p>Prefrontal cortical electrophysiological characterisations of Df(h15q13)/+ and WT littermates. Data are presented as means ± SEM. <bold>a</bold> Baseline firing frequencies. The Df(h15q13)/+ mouse had attenuated baseline firing frequencies of PrL putative fast-spiking interneurons but not principal cells. <bold>b</bold> Response amplitudes. The Df(h15q13)/+ mouse had decreased detection amplitude in PrL putative fast-spiking interneurons but not principal cells. <bold>c</bold> Neuron onset latencies. The Df(h15q13)/+ had delayed onset latencies of both pyramidal cells and putative fast-spiking interneurons following auditory stimulation. <bold>d</bold> Average cortical putative fast-spiking interneuron response. Reduced firing rates and delayed onset of Df(h15q13)/+ prelimbic interneurons relative to WT mice in the auditory double-click paradigm. <bold>e</bold> Gabazine-induced elevation of PFC pyramidal spike frequency. The Df(h15q13)/+ showed decreased sensitivity to intra-mPFC GABA<sub>A</sub>R antagonism on pyramidal neuron spike frequency. <italic>Asterisks</italic> denote <italic>p</italic> &lt; 0.05 (*<italic>p</italic> &lt; 0.05, **<italic>p</italic> &lt; 0.01, ***<italic>p</italic> &lt; 0.001)</p></caption><graphic id="MO1" xlink:href="213_2016_4265_Fig1_HTML"></graphic></fig></p>
</sec>
<sec id="Sec11">
<title>Experiment 2: cortical auditory-evoked neuron response</title>
<p>In the double-click paradigm (Fig. <xref ref-type="fig" rid="Fig1">1b–d</xref>), decreased neuron firing was observed in D(h15q13/+) interneurons (Fig. <xref ref-type="fig" rid="Fig1">1b</xref>; <italic>F</italic><sub>1,70</sub> = 6.74, <italic>p</italic> = 0.011) but not pyramidal neurons (<italic>F</italic><sub>1,239</sub> = 1.40, <italic>p</italic> = 0.238). Df(h15q13/+) interneurons (<italic>F</italic><sub>1,43</sub> = 6.64, <italic>p</italic> = 0.013) and pyramidal cells (<italic>F</italic><sub>1,146</sub> = 8.82, <italic>p</italic> = 0.003) also had increased onset latencies (Fig. <xref ref-type="fig" rid="Fig1">1c</xref>).</p>
</sec>
<sec id="Sec12">
<title>Experiment 3: intra-mPFC GABA<sub>A</sub>R antagonism and pyramidal discharge rate</title>
<p>See Supplementary Figure <xref ref-type="media" rid="MOESM1">1</xref>b for average action potential durations of cells classified as pyramidal cells. The Df(h15q13/+) mutant showed decreased pyramidal neuron response to intra-mPFC GABA<sub>A</sub>R antagonism (Fig. <xref ref-type="fig" rid="Fig1">1e</xref>). A two-way ANOVA revealed significant main effects of gabazine (<italic>F</italic><sub>1,115</sub> = 14.63, <italic>p</italic> = 0.0002; Ns = 53 and 66 for saline and gabazine, respectively), and genotype (<italic>F</italic><sub>1,115</sub> = 12.02, <italic>p</italic> = 0.0007; Ns = 67 and 52 for WT and TG, respectively) and a significant gabazine × genotype interaction (<italic>F</italic><sub>1,115</sub> = 6.23, <italic>p</italic> = 0.020). Post hoc analysis (Newman-Keuls) revealed a significant difference in firing rates between gabazine and standard recording conditions in WT mice (0.97 ± 0.26 vs. 3.58 ± 0.59 spikes/s, <italic>n</italic> = 29 and 38, respectively; <italic>p</italic> &lt; 0.00002) but not in Df(h15q13/+) mice (0.57 ± 0.16 vs. 1.12 ± 0.10 spikes/s; <italic>n</italic> = 24 and 28, respectively) (Fig. <xref ref-type="fig" rid="Fig1">1e</xref>). Hence, gabazine markedly elevated the discharge of putative pyramidal neurons in the PFC of WT mice, as previously observed in rats (Lladó-Pelfort et al. <xref ref-type="bibr" rid="CR49">2012</xref>) but not in Df(h15q13/+) mice. This suggests that the Df(h15q13/+) mouse has altered inhibitory neurotransmission in this cortical area.</p>
</sec>
<sec id="Sec13">
<title>Experiments 4-6: the touchscreen 5-CSRTT</title>
<p>Df(h15q13/+) mice showed a selective stimulus duration-dependent accuracy deficit following extended training (Fig. <xref ref-type="fig" rid="Fig2">2a–d</xref>). When manipulating the stimulus duration, there were no effects of genotype or genotype by stimulus duration interactions on <italic>initial</italic> tests using 40- or 80-trial session lengths (Supplementary Fig. <xref ref-type="media" rid="MOESM1">2</xref>a–c). However, reproducible stimulus duration-dependent impairments were observed following extended training (∼100 sessions) using 140 trials per session. Extended training improved the performance of WT animals thereby producing increased room to detect the performance decrement of the Df(h15q13)/+ mice (see Supplementary Fig. <xref ref-type="media" rid="MOESM1">2</xref>a–c).<fig id="Fig2"><label>Fig. 2</label><caption><p>Performance of Df(h15q13)/+ and WT littermates in the 5-choice serial reaction time task. Data are presented as means ± SEM. <bold>a</bold>–<bold>b</bold> Test 1—decreasing stimulus durations. The Df(h15q13)/+ mouse showed lower accuracies at shorter stimulus durations (<bold>a</bold>) but did not differ from WTs on percent omission (<bold>b</bold>). <bold>c</bold>–<bold>d</bold> Test 2—decreasing stimulus durations. The accuracy impairment in the Df(h15q13)/+ mouse was reproduced using stimulus durations between 2 and 0.2 s (<bold>c</bold>). There was again no effect of genotype on percent omission (<bold>d</bold>). <italic>Asterisks</italic> denote <italic>p</italic> &lt; 0.05 (*<italic>p</italic> &lt; 0.05, **<italic>p</italic> &lt; 0.01)</p></caption><graphic id="MO2" xlink:href="213_2016_4265_Fig2_HTML"></graphic></fig></p>
<p>When tested on 140 trials per session, the Df(h15q13/+) mice showed decreased accuracies at shorter SDs (Fig. <xref ref-type="fig" rid="Fig2">2a</xref>, genotype: <italic>F</italic><sub>1,29</sub> = 11.08, <italic>p</italic> = 0.002, genotype × SD: <italic>F</italic><sub>3,87</sub> = 5.92, <italic>p</italic> = 0.001). The Df(h15q13/+) mouse showed lower accuracies at the 0.8-s (<italic>p</italic> = 0.001) and 0.6-s SDs (<italic>p</italic> = 0.002) but not at the 1-s (<italic>p</italic> = 0.074) and 2-s SDs (<italic>p</italic> = 0.375). There were no effects of genotype or genotype × SD interaction on percent omission (Fig. <xref ref-type="fig" rid="Fig2">2b</xref>) or any other behavioural measure (<italic>p</italic> ≥ 0.20; Supplementary Table S<xref ref-type="media" rid="MOESM1">1</xref>). The accuracy impairment in the Df(h15q13/+) was reproduced in the same cohort of animals using stimulus durations between 2 and 0.2 s (Fig. <xref ref-type="fig" rid="Fig2">2c, d</xref>). Trial-bin analyses showed that Df(h15q13/+) mice had impaired accuracy throughout the length of the sessions. Thus, the deficit was not related to impaired vigilance (Supplementary Fig. <xref ref-type="media" rid="MOESM1">2</xref>a-c). No impairment was observed on test of increasing delays measuring impulsive responding (Supplementary Fig. <xref ref-type="media" rid="MOESM1">3</xref>d) and the partial α<sub>7</sub>nAChR agonist EVP-6124 did not reverse the accuracy impairment in the Df(h15q13/+) mouse (Table <xref ref-type="table" rid="Tab1">1</xref>).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Effect of systemic EVP-6124 on 5-CSRTT performance in WT and Df(h15q13)/+ mice</p></caption><table frame="hsides" rules="groups"><thead><tr><th></th><th colspan="2">% accuracy</th><th colspan="2">% omission</th></tr></thead><tbody><tr><td>Dose (mg/kg)</td><td>WT</td><td>Df(h15q13)/+</td><td>WT</td><td>Df(h15q13)/+</td></tr><tr><td>0</td><td>90.45 ± 1.06</td><td>85.55 ± 1.46</td><td>13.24 ± 1.96</td><td>17.07 ± 1.90</td></tr><tr><td>1</td><td>90.14 ± 0.91</td><td>86.84 ± 1.25</td><td>13.77 ± 2.29</td><td>17.08 ± 1.96</td></tr><tr><td>10</td><td>90.06 ± 1.14</td><td>83.70 ± 2.02</td><td>14.95 ± 1.58</td><td>20.33 ± 3.36</td></tr><tr><td>30</td><td>87.38 ± 1.07</td><td>85.02 ± 1.41</td><td>20.88 ± 2.55</td><td>22.15 ± 2.77</td></tr></tbody></table><table-wrap-foot><p>Animals were tested using a 140-trial session length, 5-s delay, and 0.8-s SD. No effect of EVP-6124 on percent accuracy (genotype: <italic>F</italic>
<sub>1,30</sub> = 8.96, <italic>p</italic> = 0.004, dose: <italic>F</italic>
<sub>3,90</sub> = 2.12, <italic>p</italic> = 0.104, dose × genotype: <italic>F</italic>
<sub>3,90</sub> = 1.51, <italic>p</italic> = 0.216). EVP-6124 increased omissions at highest dose relative to vehicle (genotype: <italic>F</italic>
<sub>1,30</sub> = 1.97, <italic>p</italic> = 0.171, dose: <italic>F</italic>
<sub>3,90</sub> = 5.10, <italic>p</italic> = 0.003, dose × genotype: <italic>F</italic>
<sub>3,90</sub> = 0.43, <italic>p</italic> = 0.735) in both Df(h15q13)/+ and WT animals</p></table-wrap-foot></table-wrap></p>
</sec>
<sec id="Sec14">
<title>Experiments 7–12: additional cognitive</title>
<sec id="FPar11">
<title>Experiment 7—visual discrimination and reversal learning</title>
<p>There was no effect of genotype on visual discrimination learning (Supplementary Fig. S<xref ref-type="media" rid="MOESM1">3</xref>a-b; <italic>p</italic> ≥ 0.441) or reversal learning (Fig. <xref ref-type="fig" rid="Fig3">3a, b</xref>; <italic>p</italic> ≥ 0.080).<fig id="Fig3"><label>Fig. 3</label><caption><p>Performance of Df(h15q13)/+ and WT littermates on tests of cognitive flexibility, working memory, motivation and learning and memory. <bold>a</bold> Reversal learning test 1—“easy” discriminable stimuli. <italic>Inset</italic> depicts the stimuli. No effect of genotype on trials to criterion, correction trials to criterion, errors to criterion, early errors, or late errors (<italic>p</italic> ≥ 0.080). <bold>b</bold> Reversal learning test 2—“challenging” stimuli. No effect of genotype on trials to criterion, correction trials to criterion, errors to criterion, early errors, or late errors (<italic>p</italic> ≥ 0.277). <bold>c</bold> Paired-associate learning (PAL). No effect of genotype on percent accuracy (<italic>p</italic> ≥ 0.103). <bold>d</bold> Progressive ratio. No effect of genotype on trials completed (<italic>p</italic> ≥ 0.321). <bold>e</bold> Extinction learning. No effect of genotype on percent responses (<italic>p</italic> ≥ 0.385). <bold>f</bold> TUNL—delay challenge. No effect of genotype on percent accuracy (<italic>p</italic> ≥ 0.692). <bold>g</bold> TUNL—pattern separation challenge. No effect of genotype on percent accuracy (<italic>p</italic> ≥ 0.302). <bold>h</bold>–<bold>i</bold> Novel object recognition. The Df(h15q13/+) mouse showed reduced discrimination ratio at the 11-h delay (trial 2: <italic>p</italic> = 0.12, trial 3: <italic>p</italic> = 0.047) and reduced sample exploration time at the 11-h delay (trial 2: <italic>p</italic> = .036; trial 3: <italic>p</italic> = 0.023). <italic>Asterisks</italic> denote differences at which <italic>p</italic> &lt; 0.05 (*<italic>p</italic> &lt; 0.05)</p></caption><graphic id="MO3" xlink:href="213_2016_4265_Fig3_HTML"></graphic></fig></p>
</sec>
<sec id="FPar12">
<title>Experiment 8—paired-associate learning (PAL)</title>
<p>There was no significant effect of genotype in the PAL task. There was no effect of genotype or genotype × session interaction on percent accuracy (Fig. <xref ref-type="fig" rid="Fig3">3c</xref>; <italic>p</italic> ≥ 0.103) or correction trials (Supplementary Fig. <xref ref-type="media" rid="MOESM1">3</xref>c; <italic>p</italic> ≥ 0.061).</p>
</sec>
<sec id="FPar13">
<title>Experiment 9—progressive ratio (PR)</title>
<p>Genotype did not affect measures of motivation in the PR task. There was no effect of genotype or genotype × PR schedule interaction on trials completed (Fig. <xref ref-type="fig" rid="Fig3">3d</xref>; <italic>p</italic> ≥ 0.321) or break points (Supplementary Fig. <xref ref-type="media" rid="MOESM1">3</xref>e; <italic>p</italic> ≥ 0.321).</p>
</sec>
<sec id="FPar14">
<title>Experiment 10—extinction learning</title>
<p>There were no effect of genotype or genotype × session interaction on percent responses in extinction learning (Fig <xref ref-type="fig" rid="Fig3">3e</xref>; <italic>p</italic> ≥ 0.385).</p>
</sec>
<sec id="FPar15">
<title>Experiment 11—trial-unique non-match to sample</title>
<p>When tested on increasing delays, there was no effect of genotype or genotype × delay interaction on percent accuracy (Fig. <xref ref-type="fig" rid="Fig3">3e</xref>; <italic>p</italic> ≥ 0.692). Similarly, there was no effect of genotype or genotype × separation interaction when tested using increasing stimuli separations (Fig. <xref ref-type="fig" rid="Fig3">3e</xref>; <italic>p</italic> ≥ 0.692). There were no effects of genotype on correction trials to criterion in either test (Supplementary Fig. <xref ref-type="media" rid="MOESM1">4</xref>f, g; <italic>p</italic> ≥ 0.683).</p>
</sec>
<sec id="FPar16">
<title>Experiment 12—novel object recognition (NOR)</title>
<p>The Df(h15q13/+) mouse showed impaired novel object recognition (Fig. <xref ref-type="fig" rid="Fig3">3h</xref>). However, this impairment was coupled with deceased sample exploration times (Fig. <xref ref-type="fig" rid="Fig3">3i</xref>) and can therefore not confidently be ascribed to a memory impairment. At the 8-h delay, there was no effect of genotype on sample exploration time or discrimination ratio (<italic>p</italic> ≥ 0.225). At the 11-h delay, the Df(h15q13/+) mouse showed decreased discrimination ratios (trial 2: <italic>p</italic> = 0.120; trial 3: <italic>p</italic> = 0.047) and decreased sample exploration times (trial 2: <italic>p</italic> = .036; trial 3: <italic>p</italic> = 0.023).</p>
</sec>
</sec>
</sec>
<sec id="Sec15" sec-type="discussion">
<title>Discussion</title>
<p>A chromosomal microdeletion at locus 15q13.3 is one of the largest known risk factors of schizophrenia and represents an ideal opportunity for back-translational study. We have previously generated a mouse model of the 15q13.3 microdeletion (Df(h15q13)/+) (Fejgin et al. <xref ref-type="bibr" rid="CR20">2014</xref>), and here, we characterised it using a variety of neurophysiological, pharmacological, and behavioural assays across multiple experimental sites. This comprehensive phenotyping revealed marked medial prefrontal cortical dysfunctions in the Df(h15q13)/+ model as measured by multiple parallel tests of inhibitory transmission and attentional functioning. These dysfunctions were observed as decreased baseline activity of putative interneuron and reduced interneuron and pyramidal neuron sensitivity to auditory stimulation. The Df(h15q13)/+ mouse also showed reduced sensitivity to intra-mPFC GABA<sub>A</sub>R blockade as measured by pyramidal neuron spike frequencies and a selective attentional impairment in the prefrontal cortical-dependent 5-CSRTT. Furthermore, we show that the attentional impairment of the Df(h15q13)/+ mouse is insensitive to systemic treatment with the partial α<sub>7</sub>nAChR agonist EVP-6124.</p>
<p>The Df(h15q13)/+ mouse showed reduced putative fast-spiking interneuron baseline activity and decreased putative pyramidal cell and fast-spiking interneuron auditory-evoked responses. These dysfunctions have clear translational relevance to schizophrenia and attentional dysfunction. For example, schizophrenia is associated with neurophysiological dysfunctions in passive sensory stimulation paradigms (2012) such as pre-attentative measures of mismatch negativity and repetition positivity (Baldeweg et al. <xref ref-type="bibr" rid="CR6">2004</xref>) and N100 amplitudes (Michie et al. <xref ref-type="bibr" rid="CR55">1990</xref>) as well as suppressed P50 gating (Adler et al. <xref ref-type="bibr" rid="CR2">1982</xref>), a phenomenon involving α<sub>7</sub>nAChRs (Freedman et al. <xref ref-type="bibr" rid="CR24">1997</xref>) coded by the <italic>CHRNA7</italic> gene for which the Df(h15q13)/+ mouse shows allelic insufficiency (Fejgin et al. <xref ref-type="bibr" rid="CR20">2014</xref>). Information processing deficits also include attenuated attentional allocation-driven cortical event-related potential P3b amplitudes (Roxborough et al. <xref ref-type="bibr" rid="CR75">1993</xref>; Weisbrod et al. <xref ref-type="bibr" rid="CR86">1999</xref>; Ford et al. <xref ref-type="bibr" rid="CR22">2001</xref>) and increased latencies of evoked potentials in visual and auditory paradigms, such as continuous performance tasks (Nieman et al. <xref ref-type="bibr" rid="CR61">2002</xref>) that reflect disrupted GABAergic (Benes and Berretta <xref ref-type="bibr" rid="CR10">2001</xref>) and cholinergic (Baldeweg et al. <xref ref-type="bibr" rid="CR7">2006</xref>) signalling efficacy. Reduction in cortical inhibition as measured by transcranial magnetic stimulation has also been observed in schizophrenic patients independent of clinical state (Fitzgerald et al. <xref ref-type="bibr" rid="CR21">2002</xref>; Daskalakis et al. <xref ref-type="bibr" rid="CR16">2002</xref>; Wobrock et al. <xref ref-type="bibr" rid="CR88">2008</xref>; Liu et al. <xref ref-type="bibr" rid="CR48">2009</xref>), and the phenotype is similarly linked to deficient cortical GABAergic transmission and attentional processes (Daskalakis et al. <xref ref-type="bibr" rid="CR17">2007</xref>). Analogous cortical neurophysiological dysfunction of auditory and visual event-related responses is also found in pharmacological animal models of schizophrenia (Bickel and Javitt <xref ref-type="bibr" rid="CR12">2009</xref>). Thus, our data indicate that the Df(h15q13)/+ mouse has decreased speed of processing and reduced recruitment of putative fast-spiking interneurons in the PrL and this phenotype corresponds with observations in schizophrenia patients. This also parallels our previous observations of reduced parietal, prelimbic, and hippocampal oscillatory activity or auditory-evoked potentials in the Df(h15q13)/+ mouse (Fejgin et al. <xref ref-type="bibr" rid="CR20">2014</xref>) which in conjunction with the current data would suggest more systemic speed of processing deficits in the mutant.</p>
<p>The Df(h15q13)/+ mouse showed prefrontal cortical GABA<sub>A</sub>R antagonist hyposensitivity with attenuated increase of putative pyramidal spike frequency in response to local (PrL + anterior cingulate) application of the GABA<sub>A</sub>R antagonist gabazine. The data parallel findings of disrupted GABAergic activity in many schizophrenia-relevant animal models, including cortical reductions in GABA-related markers (Morrow et al. <xref ref-type="bibr" rid="CR57">2007</xref>; Lodge et al. <xref ref-type="bibr" rid="CR50">2009</xref>; Francois et al. <xref ref-type="bibr" rid="CR23">2009</xref>; Ammassari-Teule et al. <xref ref-type="bibr" rid="CR5">2009</xref>) and aberrant pharmacological activation of fast-spiking interneurons (Tseng et al. <xref ref-type="bibr" rid="CR83">2008</xref>). The decreased sensitivity to PFC GABA<sub>A</sub>R blockade in Df(h15q13)/+ mice is also in agreement with histological findings in patients with schizophrenia showing reduced cortical expressions in a range of GABAergic markers, including non-pyramidal cells (1991), PV-immunoreactivity (Beasley and Reynolds <xref ref-type="bibr" rid="CR9">1997</xref>), GAD65/67 levels (Akbarian et al. <xref ref-type="bibr" rid="CR4">1995</xref>), and GAT1 (Volk et al. <xref ref-type="bibr" rid="CR85">2001</xref>). In sum, the attenuated putative pyramidal response to local GABA<sub>A</sub>R blockade in the Df(h15q13)/+ mice is in general agreement with data showing decreased GABAergic function in schizophrenia patients. The phenotype is also in agreement with the GABA<sub>A</sub>R antagonist hyposensitivity of Df(h15q13)/+ in seizure assays (Fejgin et al. <xref ref-type="bibr" rid="CR20">2014</xref>) and the decreased speed of processing and reduced baseline firing and decreased recruitment of putative fast-spiking interneurons in response to auditory stimulation.</p>
<p>We have seen no marked reduction of GABAergic markers that can account for the observed attenuation of putative interneuron basal activity or the decreased sensitivity of putative interneuron to auditory stimulation and pyramidal neuron sensitivity to GABA<sub>A</sub>R antagonism in the Df(h15q13)/+ mouse. In situ hybridization studies have nevertheless revealed a small but significant difference in prefrontal GAD expression in the Df(h15q13)/+ mutant (≤10 %; N. Santana, F. Artigas, unpublished observations). Notably, disruption of numerous transmitter processes affect cortical inhibitory control and pyramidal neuron sensitivity to GABAergic drugs (Haenschel and Linden <xref ref-type="bibr" rid="CR29">2001</xref>; Javitt et al. <xref ref-type="bibr" rid="CR39">2008</xref>; Kjaerby et al. <xref ref-type="bibr" rid="CR42">2014</xref>) and further work will be required to determine more fully the mechanisms underpinning the prefrontal cortical phenotype of the Df(h15q13)/+ mouse.</p>
<p>Importantly, the Df(h15q13)/+ mouse also exhibited a selective impairment in accuracy at shorter stimulus durations in the 5-CSRTT. This impairment was found after repeated testing improved the performance of WT animals which unmasked the deficit in the Df(h15q13)/+ mouse. The impairment was always observed throughout the sessions and therefore not related to reduced vigilance (see Supplementary Fig. S<xref ref-type="media" rid="MOESM1">2</xref>a–c). Percent accuracy is considered a primary marker of attentional control in the 5-CSRTT. Percent omission and latency measures, which can reflect motivational, sensory, or motoric factors (Robbins <xref ref-type="bibr" rid="CR73">2002</xref>), were unaffected in the Df(h15q13)/+ mouse. The accuracy impairment was also only observed at shorter stimulus duration, further indicating that the phenotype is produced by impaired attention.</p>
<p>Attentional dysfunction is at the core of the cognitive deficits of schizophrenia (Marder and Fenton <xref ref-type="bibr" rid="CR53">2004</xref>; Carter and Barch <xref ref-type="bibr" rid="CR13">2007</xref>); it can precede other symptoms (Cornblatt et al. <xref ref-type="bibr" rid="CR15">1999</xref>), predict disorder development (2001), and be present in non-affected first-degree relatives (Snitz et al. <xref ref-type="bibr" rid="CR76">2006</xref>). Thus, the observation of similar attentional deficits in the Df(h15q13)/+ mouse suggests that the model carries translational utility within this cognitive domain with possible relevance for drug discovery.</p>
<p>An attentional impairment in the 5-CSRTT can also be predicted by the prelimbic neurophysiological and GABAergic phenotypes of the Df(h15q13)/+ mouse. In animals, intra-mPFC administration of GABA<sub>A</sub>R antagonists (Paine et al. <xref ref-type="bibr" rid="CR65">2011</xref>; Pehrson et al. <xref ref-type="bibr" rid="CR68">2013</xref>; Pezze et al. <xref ref-type="bibr" rid="CR69">2014</xref>) and agonists (Paine et al. <xref ref-type="bibr" rid="CR65">2011</xref>; Pezze et al. <xref ref-type="bibr" rid="CR69">2014</xref>) decrease percent accuracy in the 5-CSRTT, indicating that imbalances in cortical inhibitory activity disrupts attention. Moreover, in a variation of the 5-CSRTT, attenuated PrL inhibitory activity can predict accuracy while being unrelated to errors of omissions and premature responding (Totah et al. <xref ref-type="bibr" rid="CR81">2009</xref>). Our observations of attenuated PrL inhibitory activity together with a selective accuracy impairment in the Df(h15q13)/+ mice are entirely consistent with this view.</p>
<p>However, Df(h15q13)/+ and WT animals did not differ in performance on tasks dependent on cognitive flexibility, working memory, visuospatial learning, and motivation. The current behavioural experiments employed a battery approach where some animals where tested sequentially on multiple touchscreen tasks, and it may be that response strategies acquired in previous assays proactively interfered with performance on later tasks thereby masking more general effects of genotype on cognition. This is however unlikely.</p>
<p>First, the Df(h15q13)/+ mouse has previously been shown to exhibit a mild cognitive phenotype; the deletion fails to affect associative learning, spatial working memory, and sensorimotor gating (Fejgin et al. <xref ref-type="bibr" rid="CR20">2014</xref>). Visual discrimination and reversal learning, spatial working memory, and fear conditioning were also recently found to be unaffected in an alternative mouse model of the 15q13.3DS (D/+) (Kogan et al. <xref ref-type="bibr" rid="CR43">2015</xref>). Our observation of normal working memory, discrimination learning, and cognitive flexibility in the Df(h15q13)/+ mutant is in comprehensive agreement with these reports. Furthermore, reproducible attentional impairments were observed following extended testing in the 5-CSRTT. If extended testing masks some cognitive phenotypes in the Df(h15q13)/+ mutant the opposite pattern should be expected, deficits should be attenuated with repeated testing and not remain stable across multiple tests.</p>
<p>Moreover, although cortical GABAergic activity is relevant for a wide range of cognitive domains, mPFC-specific GABA<sub>A</sub>R antagonism through bicucilline fails to affect reversal learning (Enomoto et al. <xref ref-type="bibr" rid="CR19">2011</xref>) and working memory as assessed in the radial-arm maze (Enomoto et al. <xref ref-type="bibr" rid="CR19">2011</xref>) and T-maze (Herremans et al. <xref ref-type="bibr" rid="CR34">1996</xref>). Attentional function therefore appears particularly sensitive to GABAergic disruption (Enomoto et al. <xref ref-type="bibr" rid="CR19">2011</xref>; Tse et al. <xref ref-type="bibr" rid="CR82">2015</xref>). Nevertheless, under the present conditions, the lack of comprehensive impairment in these assays may limit the behavioural translational potential of the Df(h15q13)/+ mouse to attentional dysfunction.</p>
<p>Reduced α<sub>7</sub>nAChR expression has been advanced as a possible mechanism underlying the neuropsychiatric phenotypes of 15q13.3DS (LePichon et al. <xref ref-type="bibr" rid="CR44">2010</xref>; Hoppman-Chaney et al. <xref ref-type="bibr" rid="CR35">2013</xref>), and decreased cortical α<sub>7</sub>nAChR-expression is a mechanistic candidate for the Df(h15q13)/+ phenotype. α<sub>7</sub>nAChRs are expressed in parvalbumin-positive GABAergic fast-spiking interneurons (Murakami et al. <xref ref-type="bibr" rid="CR59">2013</xref>), <italic>Chrna7</italic> deletion causes dysregulated cortical inhibitory activity (Adams et al. <xref ref-type="bibr" rid="CR1">2012</xref>; Lin et al. <xref ref-type="bibr" rid="CR47">2014</xref>), and <italic>Chrna7</italic><sup>-/-</sup> mice show retarded performance in the 5-CSRTT (Young et al. <xref ref-type="bibr" rid="CR89">2004</xref>; Hoyle et al. <xref ref-type="bibr" rid="CR37">2006</xref>; Young et al. <xref ref-type="bibr" rid="CR90">2007</xref>).</p>
<p>However, acute dosing with the partial α<sub>7</sub>nAChR agonist EVP-6124 did not attenuate the attentional deficit in Df(h15q13)/+ mice. The lack of acute effect may be explained by reduced cortical α<sub>7</sub>nAChR expression leading to insufficient number of channels to be activated (full agonist treatment or chronic dosing may be required for efficacy) or by rapid agonist-induced receptor desensitisation leading to functional inactivation of the α<sub>7</sub>nAChR at the EVP-6124 doses used. Nevertheless, α<sub>7</sub>nAChR agonists have often failed to affect attentional measures in schizophrenic patients (Olincy et al. <xref ref-type="bibr" rid="CR62">2006</xref>; Freedman et al. <xref ref-type="bibr" rid="CR25">2008</xref>; Lieberman et al. <xref ref-type="bibr" rid="CR46">2013</xref>; Preskorn et al. <xref ref-type="bibr" rid="CR70">2014</xref>; Umbricht et al. <xref ref-type="bibr" rid="CR84">2014</xref>) and rodent 5-CSRTT performance (Grottick et al. <xref ref-type="bibr" rid="CR28">2003</xref>; Hahn et al. <xref ref-type="bibr" rid="CR30">2003</xref>; Hoyle et al. <xref ref-type="bibr" rid="CR37">2006</xref>). In accordance with this, we found EVP-6124 to be ineffective against the attentional impairment in the Df(h15q13)/+ mice. Thus, although decreased α<sub>7</sub>nAChR expression may cause cortical neurophysiological and attentional deficits, data indicate that α<sub>7</sub>nAChR agonism does not produce sufficient efficacy or that the mechanism underlying the phenotype may be downstream from the α<sub>7</sub>nAChR receptor or due to the functional importance of the deletion of other genes in the CNV region (Fejgin et al. <xref ref-type="bibr" rid="CR20">2014</xref>).</p>
<p>In sum, we observed multiple dysfunctions converging on disrupted medial prefrontal cortical functioning in the Df(h15q13)/+ mouse. These dysfunctions were observed as (i) decreased baseline firing and attenuated auditory-evoked responses of putative inhibitory interneurons and (ii) reduced putative pyramidal cell sensitivity to local GABA<sub>A</sub>R antagonism and (iii) selective decrease in percent accuracy in the 5-CSRTT. These data parallel the phenotypes of 15q13.3DS-related neuropsychiatric disorders and indicate that the Df(h15q13)/+ mouse has translational relevance for modelling some cortical dysfunctions associated with schizophrenia.</p>
</sec>
<sec sec-type="supplementary-material">
<title>Electronic supplementary material</title>
<sec id="Sec16">
<p>Below is the link to the electronic supplementary material.<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="213_2016_4265_MOESM1_ESM.docx"><label>ESM 1</label><caption><p>(DOCX 936 kb)</p></caption></media></supplementary-material></p>
</sec>
</sec>
</body>
<back>
<fn-group>
<fn>
<p>Timothy J. Bussey, Francesc Artigas and Michael Didriksen contributed equally to this work.</p>
</fn>
</fn-group>
<ack>
<p>The research leading to these results has received support from the Innovative Medicine Initiative Joint Undertaking under grant agreement no. 115008 of which resources are composed of EFPIA in-kind contribution and financial contribution from the European Union’s Seventh Framework Programme (FP7/2007-2013). The Behavioural and Clinical Neuroscience Institute is co-funded by the Medical Research Council and the Wellcome Trust. This study was also supported by the Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM). The authors would like to thank Mercedes Nuñez, Noemí Jurado, Edita Bulovaitė, Sueda Tunçak, Lewis Buss, and Diab Ali for the skillful technical assistance.</p>
</ack>
<ref-list id="Bib1">
<title>References</title>
<ref id="CR1">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Adams</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Yonchek</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Schulz</surname>
<given-names>KM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Reduced Chrna7 expression in mice is associated with decreases in hippocampal markers of inhibitory function: implications for neuropsychiatric diseases</article-title>
<source/>Neuroscience
          <year>2012</year>
<volume>207</volume>
<fpage>274</fpage>
<lpage>282</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuroscience.2012.01.033</pub-id>
<pub-id pub-id-type="pmid">22314319</pub-id>
</element-citation>
</ref>
<ref id="CR2">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Adler</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Pachtman</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Franks</surname>
<given-names>RD</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Neurophysiological evidence for a defect in neuronal mechanisms involved in sensory gating in schizophrenia</article-title>
<source/>Biol Psychiat
          <year>1982</year>
<volume>17</volume>
<fpage>639</fpage>
<lpage>654</lpage>
<pub-id pub-id-type="pmid">7104417</pub-id>
</element-citation>
</ref>
<ref id="CR3">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Adler</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Olincy</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Waldo</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Schizophrenia, sensory gating, and nicotinic receptors</article-title>
<source/>Schizophr Bull
          <year>1998</year>
<volume>24</volume>
<fpage>189</fpage>
<lpage>202</lpage>
<pub-id pub-id-type="doi">10.1093/oxfordjournals.schbul.a033320</pub-id>
<pub-id pub-id-type="pmid">9613620</pub-id>
</element-citation>
</ref>
<ref id="CR4">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Akbarian</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Potkin</surname>
<given-names>SG</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics</article-title>
<source/>Arch Gen Psychiat
          <year>1995</year>
<volume>52</volume>
<fpage>258</fpage>
<lpage>266</lpage>
<pub-id pub-id-type="doi">10.1001/archpsyc.1995.03950160008002</pub-id>
<pub-id pub-id-type="pmid">7702443</pub-id>
</element-citation>
</ref>
<ref id="CR5">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ammassari-Teule</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sgobio</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Biamonte</surname>
<given-names>F</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Reelin haploinsufficiency reduces the density of PV+ neurons in circumscribed regions of the striatum and selectively alters striatal-based behaviors</article-title>
<source/>Psychopharmacology
          <year>2009</year>
<volume>204</volume>
<fpage>511</fpage>
<lpage>521</lpage>
<pub-id pub-id-type="doi">10.1007/s00213-009-1483-x</pub-id>
<pub-id pub-id-type="pmid">19277610</pub-id>
</element-citation>
</ref>
<ref id="CR6">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baldeweg</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Klugman</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gruzelier</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hirsch</surname>
<given-names>SR</given-names>
</name>
</person-group>
<article-title>Mismatch negativity potentials and cognitive impairment in schizophrenia</article-title>
<source/>Schizophrn Res
          <year>2004</year>
<volume>69</volume>
<fpage>203</fpage>
<lpage>217</lpage>
<pub-id pub-id-type="doi">10.1016/j.schres.2003.09.009</pub-id>
</element-citation>
</ref>
<ref id="CR7">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baldeweg</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Stephan</surname>
<given-names>KE</given-names>
</name>
</person-group>
<article-title>Nicotinic modulation of human auditory sensory memory: evidence from mismatch negativity potentials</article-title>
<source/>Int J Psychophysiol
          <year>2006</year>
<volume>59</volume>
<fpage>49</fpage>
<lpage>58</lpage>
<pub-id pub-id-type="doi">10.1016/j.ijpsycho.2005.07.014</pub-id>
<pub-id pub-id-type="pmid">16313986</pub-id>
</element-citation>
</ref>
<ref id="CR8">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barthó</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Hirase</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Monconduit</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Characterization of neocortical principal cells and interneurons by network interactions and extracellular features</article-title>
<source/>J Neurophysiol
          <year>2004</year>
<volume>92</volume>
<fpage>600</fpage>
<lpage>608</lpage>
<pub-id pub-id-type="doi">10.1152/jn.01170.2003</pub-id>
<pub-id pub-id-type="pmid">15056678</pub-id>
</element-citation>
</ref>
<ref id="CR9">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beasley</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Reynolds</surname>
<given-names>GP</given-names>
</name>
</person-group>
<article-title>Parvalbumin-immunoreactive neurons are reduced in the prefrontal cortex of schizophrenics</article-title>
<source/>Schizophrn Res
          <year>1997</year>
<volume>24</volume>
<fpage>349</fpage>
<lpage>355</lpage>
<pub-id pub-id-type="doi">10.1016/S0920-9964(96)00122-3</pub-id>
</element-citation>
</ref>
<ref id="CR10">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Benes</surname>
<given-names>FM</given-names>
</name>
<name>
<surname>Berretta</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder</article-title>
<source/>Neuropsychopharmacol
          <year>2001</year>
<volume>25</volume>
<fpage>1</fpage>
<lpage>27</lpage>
<pub-id pub-id-type="doi">10.1016/S0893-133X(01)00225-1</pub-id>
</element-citation>
</ref>
<ref id="CR11">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ben-Shachar</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lanpher</surname>
<given-names>B</given-names>
</name>
<name>
<surname>German</surname>
<given-names>JR</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Microdeletion 15q13.3: a locus with incomplete penetrance for autism, mental retardation, and psychiatric disorders</article-title>
<source/>J Med Genet
          <year>2009</year>
<volume>46</volume>
<fpage>382</fpage>
<lpage>388</lpage>
<pub-id pub-id-type="doi">10.1136/jmg.2008.064378</pub-id>
<pub-id pub-id-type="pmid">19289393</pub-id>
</element-citation>
</ref>
<ref id="CR12">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bickel</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Javitt</surname>
<given-names>DC</given-names>
</name>
</person-group>
<article-title>Neurophysiological and neurochemical animal models of schizophrenia: focus on glutamate</article-title>
<source/>Behav Brain Res
          <year>2009</year>
<volume>204</volume>
<fpage>352</fpage>
<lpage>362</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbr.2009.05.005</pub-id>
<pub-id pub-id-type="pmid">19433116</pub-id>
</element-citation>
</ref>
<ref id="CR13">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carter</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Barch</surname>
<given-names>DM</given-names>
</name>
</person-group>
<article-title>Cognitive neuroscience-based approaches to measuring and improving treatment effects on cognition in schizophrenia: the CNTRICS initiative</article-title>
<source/>Schizophr Bull
          <year>2007</year>
<volume>33</volume>
<fpage>1131</fpage>
<lpage>1137</lpage>
<pub-id pub-id-type="doi">10.1093/schbul/sbm081</pub-id>
<pub-id pub-id-type="pmid">17630405</pub-id>
</element-citation>
</ref>
<ref id="CR14">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chudasama</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Muir</surname>
<given-names>JL</given-names>
</name>
</person-group>
<article-title>Visual attention in the rat: a role for the prelimbic cortex and thalamic nuclei?</article-title>
<source/>Behav Neurosci
          <year>2001</year>
<volume>115</volume>
<fpage>417</fpage>
<lpage>428</lpage>
<pub-id pub-id-type="doi">10.1037/0735-7044.115.2.417</pub-id>
<pub-id pub-id-type="pmid">11345966</pub-id>
</element-citation>
</ref>
<ref id="CR15">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cornblatt</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Obuchowski</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Roberts</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cognitive and behavioral precursors of schizophrenia</article-title>
<source/>Dev Psychopathol
          <year>1999</year>
<volume>11</volume>
<fpage>487</fpage>
<lpage>508</lpage>
<pub-id pub-id-type="doi">10.1017/S0954579499002175</pub-id>
<pub-id pub-id-type="pmid">10532621</pub-id>
</element-citation>
</ref>
<ref id="CR16">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Daskalakis</surname>
<given-names>ZJ</given-names>
</name>
<name>
<surname>Christensen</surname>
<given-names>BK</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Evidence for impaired cortical inhibition in schizophrenia using transcranial magnetic stimulation</article-title>
<source/>Arch Gen Psychiat
          <year>2002</year>
<volume>59</volume>
<fpage>347</fpage>
<lpage>354</lpage>
<pub-id pub-id-type="doi">10.1001/archpsyc.59.4.347</pub-id>
<pub-id pub-id-type="pmid">11926935</pub-id>
</element-citation>
</ref>
<ref id="CR17">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Daskalakis</surname>
<given-names>ZJ</given-names>
</name>
<name>
<surname>Fitzgerald</surname>
<given-names>PB</given-names>
</name>
<name>
<surname>Christensen</surname>
<given-names>BK</given-names>
</name>
</person-group>
<article-title>The role of cortical inhibition in the pathophysiology and treatment of schizophrenia</article-title>
<source/>Brain Res Rev
          <year>2007</year>
<volume>56</volume>
<fpage>427</fpage>
<lpage>442</lpage>
<pub-id pub-id-type="doi">10.1016/j.brainresrev.2007.09.006</pub-id>
<pub-id pub-id-type="pmid">17980435</pub-id>
</element-citation>
</ref>
<ref id="CR18">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Debarbieux</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Brunton</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Charpak</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Effect of bicuculline on thalamic activity: a direct blockade of IAHP in reticularis neurons</article-title>
<source/>J Neurophysiol
          <year>1998</year>
<volume>79</volume>
<fpage>2911</fpage>
<lpage>2918</lpage>
<pub-id pub-id-type="pmid">9636097</pub-id>
</element-citation>
</ref>
<ref id="CR19">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Enomoto</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Tse</surname>
<given-names>MT</given-names>
</name>
<name>
<surname>Floresco</surname>
<given-names>SB</given-names>
</name>
</person-group>
<article-title>Reducing prefrontal gamma-aminobutyric acid activity induces cognitive, behavioral, and dopaminergic abnormalities that resemble schizophrenia</article-title>
<source/>Biol Psychiat
          <year>2011</year>
<volume>69</volume>
<fpage>432</fpage>
<lpage>441</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2010.09.038</pub-id>
<pub-id pub-id-type="pmid">21146155</pub-id>
</element-citation>
</ref>
<ref id="CR20">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fejgin</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Nielsen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Birknow</surname>
<given-names>MR</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A mouse model that recapitulates cardinal features of the 15q13.3 microdeletion syndrome including schizophrenia- and epilepsy-related alterations</article-title>
<source/>Biol Psychiat
          <year>2014</year>
<volume>76</volume>
<fpage>128</fpage>
<lpage>137</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2013.08.014</pub-id>
<pub-id pub-id-type="pmid">24090792</pub-id>
</element-citation>
</ref>
<ref id="CR21">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fitzgerald</surname>
<given-names>PB</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>TL</given-names>
</name>
<name>
<surname>Daskalakis</surname>
<given-names>ZJ</given-names>
</name>
<name>
<surname>Kulkarni</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>A transcranial magnetic stimulation study of inhibitory deficits in the motor cortex in patients with schizophrenia</article-title>
<source/>Psychiat Res
          <year>2002</year>
<volume>114</volume>
<fpage>11</fpage>
<lpage>22</lpage>
<pub-id pub-id-type="doi">10.1016/S0925-4927(02)00002-1</pub-id>
</element-citation>
</ref>
<ref id="CR22">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ford</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Mathalon</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>Kalba</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>N1 and P300 abnormalities in patients with schizophrenia, epilepsy, and epilepsy with schizophrenialike features</article-title>
<source/>Biol Psychiat
          <year>2001</year>
<volume>49</volume>
<fpage>848</fpage>
<lpage>860</lpage>
<pub-id pub-id-type="doi">10.1016/S0006-3223(00)01051-9</pub-id>
<pub-id pub-id-type="pmid">11343681</pub-id>
</element-citation>
</ref>
<ref id="CR23">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Francois</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ferrandon</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Koning</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Selective reorganization of GABAergic transmission in neonatal ventral hippocampal-lesioned rats</article-title>
<source/>Int J Neuropsychopharm
          <year>2009</year>
<volume>12</volume>
<fpage>1097</fpage>
<pub-id pub-id-type="doi">10.1017/S1461145709009985</pub-id>
</element-citation>
</ref>
<ref id="CR24">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Freedman</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Coon</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Myles-Worsley</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>1997</year>
<volume>94</volume>
<fpage>587</fpage>
<lpage>592</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.94.2.587</pub-id>
<pub-id pub-id-type="pmid">9012828</pub-id>
</element-citation>
</ref>
<ref id="CR25">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Freedman</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Olincy</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Buchanan</surname>
<given-names>RW</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Initial phase 2 trial of a nicotinic agonist in schizophrenia</article-title>
<source/>Am J Psychiatry
          <year>2008</year>
<volume>165</volume>
<fpage>1040</fpage>
<lpage>1047</lpage>
<pub-id pub-id-type="doi">10.1176/appi.ajp.2008.07071135</pub-id>
<pub-id pub-id-type="pmid">18381905</pub-id>
</element-citation>
</ref>
<ref id="CR26">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Garay</surname>
<given-names>RP</given-names>
</name>
<name>
<surname>Citrome</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Samalin</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries</article-title>
<source/>Expert Opin Pharmacother
          <year>2016</year>
<pub-id pub-id-type="pmid">26831200</pub-id>
</element-citation>
</ref>
<ref id="CR27">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gillentine</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Schaaf</surname>
<given-names>CP</given-names>
</name>
</person-group>
<article-title>The human clinical phenotypes of altered CHRNA7 copy number</article-title>
<source/>Biochem Pharmacol
          <year>2015</year>
<volume>97</volume>
<fpage>352</fpage>
<lpage>362</lpage>
<pub-id pub-id-type="doi">10.1016/j.bcp.2015.06.012</pub-id>
<pub-id pub-id-type="pmid">26095975</pub-id>
</element-citation>
</ref>
<ref id="CR28">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grottick</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Haman</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wyler</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Higgins</surname>
<given-names>GA</given-names>
</name>
</person-group>
<article-title>Reversal of a vigilance decrement in the aged rat by subtype-selective nicotinic ligands</article-title>
<source/>Neuropsychopharmacol
          <year>2003</year>
<volume>28</volume>
<fpage>880</fpage>
<lpage>887</lpage>
</element-citation>
</ref>
<ref id="CR29">
<mixed-citation publication-type="other">Haenschel C, Linden D (2001) Neurophysiology of cognitive dysfunction in schizophrenia. In: Ritsner MS (ed) Handbook of schizophrenia spectrum disorders: phenotypic and endophenotypic presentations. Springer, pp 449–480</mixed-citation>
</ref>
<ref id="CR30">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hahn</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Sharples</surname>
<given-names>CGV</given-names>
</name>
<name>
<surname>Wonnacott</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Attentional effects of nicotinic agonists in rats</article-title>
<source/>Neuropharmacology
          <year>2003</year>
<volume>44</volume>
<fpage>1054</fpage>
<lpage>1067</lpage>
<pub-id pub-id-type="doi">10.1016/S0028-3908(03)00099-6</pub-id>
<pub-id pub-id-type="pmid">12763099</pub-id>
</element-citation>
</ref>
<ref id="CR31">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hajos</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hurst</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Hoffmann</surname>
<given-names>WE</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The selective alpha7 nicotinic acetylcholine receptor agonist PNU-282987 [N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-4-chlorobenzamide hydrochloride] enhances GABAergic synaptic activity in brain slices and restores auditory gating deficits in anesthetized rats</article-title>
<source/>J Pharmacol Exp Ther
          <year>2005</year>
<volume>312</volume>
<fpage>1213</fpage>
<lpage>1222</lpage>
<pub-id pub-id-type="doi">10.1124/jpet.104.076968</pub-id>
<pub-id pub-id-type="pmid">15523001</pub-id>
</element-citation>
</ref>
<ref id="CR32">
<mixed-citation publication-type="other">Heath CJ, Bussey TJ, Saksida LM (2015) Motivational assessment of mice using the touchscreen operant testing system: effects of dopaminergic drugs. Psychopharmacology 1–15. doi: 10.1007/s00213-015-4009-8</mixed-citation>
</ref>
<ref id="CR33">
<mixed-citation publication-type="other">Helbig I, Mefford HC, Sharp AJ, Guipponi M, Fichera M, Franke A, Muhle H, de Kovel C, Baker C, von Spiczak S, Kron KL, Steinich I, zlig-Lie AAK, Leu C, Gaus V, Schmitz B, Klein KM, Reif PS, Rosenow F, Weber Y, Lerche H, Zimprich F, Urak L, Fuchs K, Feucht M, Genton P, Thomas P, Visscher F, de Haan GJ, Møller RS, Hjalgrim H, Luciano D, Wittig M, Nothnagel M, Elger CE, Nürnberg P, Romano C, Malafosse A, Koeleman BPC, Lindhout D, Stephani U, Schreiber S, Eichler EE, Sander T (2009) 15q13.3 microdeletions increase risk of idiopathic generalized epilepsy. Nat Genet 41:160–162. doi:10.1038/ng.292</mixed-citation>
</ref>
<ref id="CR34">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Herremans</surname>
<given-names>AH</given-names>
</name>
<name>
<surname>Hijzen</surname>
<given-names>TH</given-names>
</name>
<name>
<surname>Welborn</surname>
<given-names>PF</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Effects of infusion of cholinergic drugs into the prefrontal cortex area on delayed matching to position performance in the rat</article-title>
<source/>Brain Res
          <year>1996</year>
<volume>711</volume>
<fpage>102</fpage>
<lpage>111</lpage>
<pub-id pub-id-type="doi">10.1016/0006-8993(95)01404-7</pub-id>
<pub-id pub-id-type="pmid">8680852</pub-id>
</element-citation>
</ref>
<ref id="CR35">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hoppman-Chaney</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Wain</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Seger</surname>
<given-names>PR</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Identification of single gene deletions at 15q13.3: further evidence that CHRNA7 causes the 15q13.3 microdeletion syndrome phenotype</article-title>
<source/>Clin Genet
          <year>2013</year>
<volume>83</volume>
<fpage>345</fpage>
<lpage>351</lpage>
<pub-id pub-id-type="doi">10.1111/j.1399-0004.2012.01925.x</pub-id>
<pub-id pub-id-type="pmid">22775350</pub-id>
</element-citation>
</ref>
<ref id="CR36">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Horner</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Heath</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Hvoslef-Eide</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The touchscreen operant platform for testing learning and memory in rats and mice</article-title>
<source/>Nat Protoc
          <year>2013</year>
<volume>8</volume>
<fpage>1961</fpage>
<lpage>1984</lpage>
<pub-id pub-id-type="doi">10.1038/nprot.2013.122</pub-id>
<pub-id pub-id-type="pmid">24051959</pub-id>
</element-citation>
</ref>
<ref id="CR37">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hoyle</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Genn</surname>
<given-names>RF</given-names>
</name>
<name>
<surname>Fernandes</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Stolerman</surname>
<given-names>IP</given-names>
</name>
</person-group>
<article-title>Impaired performance of alpha7 nicotinic receptor knockout mice in the five-choice serial reaction time task</article-title>
<source/>Psychopharmacology
          <year>2006</year>
<volume>189</volume>
<fpage>211</fpage>
<lpage>223</lpage>
<pub-id pub-id-type="doi">10.1007/s00213-006-0549-2</pub-id>
<pub-id pub-id-type="pmid">17019565</pub-id>
</element-citation>
</ref>
<ref id="CR38">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<collab>International Schizophrenia Consortium</collab>
</person-group>
<article-title>Rare chromosomal deletions and duplications increase risk of schizophrenia</article-title>
<source/>Nature
          <year>2008</year>
<volume>455</volume>
<fpage>237</fpage>
<lpage>241</lpage>
<pub-id pub-id-type="doi">10.1038/nature07239</pub-id>
<pub-id pub-id-type="pmid">18668038</pub-id>
</element-citation>
</ref>
<ref id="CR39">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Javitt</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Spencer</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Thaker</surname>
<given-names>GK</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Neurophysiological biomarkers for drug development in schizophrenia</article-title>
<source/>Nat Rev Drug Discov
          <year>2008</year>
<volume>7</volume>
<fpage>68</fpage>
<lpage>83</lpage>
<pub-id pub-id-type="doi">10.1038/nrd2463</pub-id>
<pub-id pub-id-type="pmid">18064038</pub-id>
</element-citation>
</ref>
<ref id="CR40">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kahn</surname>
<given-names>PV</given-names>
</name>
<name>
<surname>Walker</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>TS</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Standardizing the use of the continuous performance test in schizophrenia research: a validation study</article-title>
<source/>Schizophrn Res
          <year>2012</year>
<volume>142</volume>
<fpage>153</fpage>
<lpage>158</lpage>
<pub-id pub-id-type="doi">10.1016/j.schres.2012.09.009</pub-id>
</element-citation>
</ref>
<ref id="CR41">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Romberg</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Hvoslef-Eide</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Trial-unique, delayed nonmatching-to-location (TUNL) touchscreen testing for mice: sensitivity to dorsal hippocampal dysfunction</article-title>
<source/>Psychopharmacology
          <year>2015</year>
<volume>232</volume>
<fpage>3935</fpage>
<lpage>3945</lpage>
<pub-id pub-id-type="doi">10.1007/s00213-015-4017-8</pub-id>
<pub-id pub-id-type="pmid">26173611</pub-id>
</element-citation>
</ref>
<ref id="CR42">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kjaerby</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Broberg</surname>
<given-names>BV</given-names>
</name>
<name>
<surname>Kristiansen</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Dalby</surname>
<given-names>NO</given-names>
</name>
</person-group>
<article-title>Impaired GABAergic inhibition in the prefrontal cortex of early postnatal phencyclidine (PCP)-treated rats</article-title>
<source/>Cereb Cortex
          <year>2014</year>
<volume>24</volume>
<fpage>2522</fpage>
<lpage>2532</lpage>
<pub-id pub-id-type="doi">10.1093/cercor/bht109</pub-id>
<pub-id pub-id-type="pmid">23613110</pub-id>
</element-citation>
</ref>
<ref id="CR43">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kogan</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gross</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Shin</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Mouse model of chromosome 15q13. 3 microdeletion syndrome demonstrates features of autism spectrum disorder</article-title>
<source/>J Neurosci
          <year>2015</year>
<volume>35</volume>
<fpage>16282</fpage>
<lpage>16294</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.3967-14.2015</pub-id>
<pub-id pub-id-type="pmid">26658876</pub-id>
</element-citation>
</ref>
<ref id="CR44">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>LePichon</surname>
<given-names>J-B</given-names>
</name>
<name>
<surname>Bittel</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Graf</surname>
<given-names>WD</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>A 15q13.3 homozygous microdeletion associated with a severe neurodevelopmental disorder suggests putative functions of the TRPM1, CHRNA7, and other homozygously deleted genes</article-title>
<source/>Am J Med Genet
          <year>2010</year>
<volume>152A</volume>
<fpage>1300</fpage>
<lpage>1304</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.a.33374</pub-id>
<pub-id pub-id-type="pmid">20425840</pub-id>
</element-citation>
</ref>
<ref id="CR45">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lewis</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Hashimoto</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Volk</surname>
<given-names>DW</given-names>
</name>
</person-group>
<article-title>Cortical inhibitory neurons and schizophrenia</article-title>
<source/>Nat Rev Neurosci
          <year>2005</year>
<volume>6</volume>
<fpage>312</fpage>
<lpage>324</lpage>
<pub-id pub-id-type="doi">10.1038/nrn1648</pub-id>
<pub-id pub-id-type="pmid">15803162</pub-id>
</element-citation>
</ref>
<ref id="CR46">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lieberman</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Dunbar</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Segreti</surname>
<given-names>AC</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A randomized exploratory trial of an α-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia</article-title>
<source/>Neuropsychopharm
          <year>2013</year>
<volume>38</volume>
<fpage>968</fpage>
<lpage>975</lpage>
<pub-id pub-id-type="doi">10.1038/npp.2012.259</pub-id>
</element-citation>
</ref>
<ref id="CR47">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Hsu</surname>
<given-names>F-C</given-names>
</name>
<name>
<surname>Baumann</surname>
<given-names>BH</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cortical parvalbumin GABAergic deficits with α7 nicotinic acetylcholine receptor deletion: implications for schizophrenia</article-title>
<source/>Mol Cell Neurosci
          <year>2014</year>
<volume>61</volume>
<fpage>163</fpage>
<lpage>175</lpage>
<pub-id pub-id-type="doi">10.1016/j.mcn.2014.06.007</pub-id>
<pub-id pub-id-type="pmid">24983521</pub-id>
</element-citation>
</ref>
<ref id="CR48">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>S-K</given-names>
</name>
<name>
<surname>Fitzgerald</surname>
<given-names>PB</given-names>
</name>
<name>
<surname>Daigle</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The relationship between cortical inhibition, antipsychotic treatment, and the symptoms of schizophrenia</article-title>
<source/>Biol Psychiat
          <year>2009</year>
<volume>65</volume>
<fpage>503</fpage>
<lpage>509</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2008.09.012</pub-id>
<pub-id pub-id-type="pmid">18950746</pub-id>
</element-citation>
</ref>
<ref id="CR49">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lladó-Pelfort</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Santana</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Ghisi</surname>
<given-names>V</given-names>
</name>
<etal></etal>
</person-group>
<article-title>5-HT1A receptor agonists enhance pyramidal cell firing in prefrontal cortex through a preferential action on GABA interneurons</article-title>
<source/>Cereb Cortex
          <year>2012</year>
<volume>22</volume>
<fpage>1487</fpage>
<lpage>1497</lpage>
<pub-id pub-id-type="doi">10.1093/cercor/bhr220</pub-id>
<pub-id pub-id-type="pmid">21893679</pub-id>
</element-citation>
</ref>
<ref id="CR50">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lodge</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Behrens</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Grace</surname>
<given-names>AA</given-names>
</name>
</person-group>
<article-title>A loss of parvalbumin-containing interneurons is associated with diminished oscillatory activity in an animal model of schizophrenia</article-title>
<source/>J Neurosci
          <year>2009</year>
<volume>29</volume>
<fpage>2344</fpage>
<lpage>2354</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.5419-08.2009</pub-id>
<pub-id pub-id-type="pmid">19244511</pub-id>
</element-citation>
</ref>
<ref id="CR51">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lowther</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Costain</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Stavropoulos</surname>
<given-names>DJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Delineating the 15q13.3 microdeletion phenotype: a case series and comprehensive review of the literature</article-title>
<source/>Genet Med
          <year>2014</year>
<volume>17</volume>
<fpage>149</fpage>
<lpage>157</lpage>
<pub-id pub-id-type="doi">10.1038/gim.2014.83</pub-id>
<pub-id pub-id-type="pmid">25077648</pub-id>
</element-citation>
</ref>
<ref id="CR52">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mar</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Horner</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Nilsson</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The touchscreen operant platform for assessing executive function in rats and mice</article-title>
<source/>Nat Protoc
          <year>2013</year>
<volume>8</volume>
<fpage>1985</fpage>
<lpage>2005</lpage>
<pub-id pub-id-type="doi">10.1038/nprot.2013.123</pub-id>
<pub-id pub-id-type="pmid">24051960</pub-id>
</element-citation>
</ref>
<ref id="CR53">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marder</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Fenton</surname>
<given-names>W</given-names>
</name>
</person-group>
<article-title>Measurement and treatment research to improve cognition in schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia</article-title>
<source/>Schizophrn Res
          <year>2004</year>
<volume>72</volume>
<fpage>5</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1016/j.schres.2004.09.010</pub-id>
</element-citation>
</ref>
<ref id="CR54">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Melchior</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Bertelsen</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Debes</surname>
<given-names>NM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Microduplication of 15q13.3 and Xq21.31 in a family with Tourette syndrome and comorbidities</article-title>
<source/>Am J Med Genet
          <year>2013</year>
<volume>162</volume>
<fpage>825</fpage>
<lpage>831</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.b.32186</pub-id>
<pub-id pub-id-type="pmid">23894120</pub-id>
</element-citation>
</ref>
<ref id="CR55">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Michie</surname>
<given-names>PT</given-names>
</name>
<name>
<surname>Fox</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Ward</surname>
<given-names>PB</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Event-related potential indices of selective attention and cortical lateralization in schizophrenia</article-title>
<source/>Psychophysiology
          <year>1990</year>
<volume>27</volume>
<fpage>209</fpage>
<lpage>227</lpage>
<pub-id pub-id-type="doi">10.1111/j.1469-8986.1990.tb00372.x</pub-id>
<pub-id pub-id-type="pmid">2247551</pub-id>
</element-citation>
</ref>
<ref id="CR56">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miller</surname>
<given-names>DT</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Weiss</surname>
<given-names>LA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Microdeletion/duplication at 15q13.2q13.3 among individuals with features of autism and other neuropsychiatric disorders</article-title>
<source/>J Med Genet
          <year>2009</year>
<volume>46</volume>
<fpage>242</fpage>
<lpage>248</lpage>
<pub-id pub-id-type="doi">10.1136/jmg.2008.059907</pub-id>
<pub-id pub-id-type="pmid">18805830</pub-id>
</element-citation>
</ref>
<ref id="CR57">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morrow</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Elsworth</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Roth</surname>
<given-names>RH</given-names>
</name>
</person-group>
<article-title>Repeated phencyclidine in monkeys results in loss of parvalbumin-containing axo-axonic projections in the prefrontal cortex</article-title>
<source/>Psychopharmacology
          <year>2007</year>
<volume>192</volume>
<fpage>283</fpage>
<lpage>290</lpage>
<pub-id pub-id-type="doi">10.1007/s00213-007-0708-0</pub-id>
<pub-id pub-id-type="pmid">17265073</pub-id>
</element-citation>
</ref>
<ref id="CR58">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Muir</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Everitt</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Robbins</surname>
<given-names>TW</given-names>
</name>
</person-group>
<article-title>The cerebral cortex of the rat and visual attentional function: dissociable effects of mediofrontal, cingulate, anterior dorsolateral, and parietal cortex lesions on a five-choice serial reaction time task</article-title>
<source/>Cereb Cortex
          <year>1996</year>
<volume>6</volume>
<fpage>470</fpage>
<lpage>481</lpage>
<pub-id pub-id-type="doi">10.1093/cercor/6.3.470</pub-id>
<pub-id pub-id-type="pmid">8670672</pub-id>
</element-citation>
</ref>
<ref id="CR59">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Murakami</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Ishikawa</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Sato</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Localization of α7 nicotinic acetylcholine receptor immunoreactivity on GABAergic interneurons in layers I-III of the rat retrosplenial granular cortex</article-title>
<source/>Neuroscience
          <year>2013</year>
<volume>252</volume>
<fpage>443</fpage>
<lpage>459</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuroscience.2013.08.024</pub-id>
<pub-id pub-id-type="pmid">23985568</pub-id>
</element-citation>
</ref>
<ref id="CR60">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nakazawa</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Zsiros</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>Z</given-names>
</name>
<etal></etal>
</person-group>
<article-title>GABAergic interneuron origin of schizophrenia pathophysiology</article-title>
<source/>Neuropharmacology
          <year>2012</year>
<volume>62</volume>
<fpage>1574</fpage>
<lpage>1583</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuropharm.2011.01.022</pub-id>
<pub-id pub-id-type="pmid">21277876</pub-id>
</element-citation>
</ref>
<ref id="CR61">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nieman</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>Koelman</surname>
<given-names>JHTM</given-names>
</name>
<name>
<surname>Linszen</surname>
<given-names>DH</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Clinical and neuropsychological correlates of the P300 in schizophrenia</article-title>
<source/>Schizophrn Res
          <year>2002</year>
<volume>55</volume>
<fpage>105</fpage>
<lpage>113</lpage>
<pub-id pub-id-type="doi">10.1016/S0920-9964(01)00184-0</pub-id>
</element-citation>
</ref>
<ref id="CR62">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Olincy</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Harris</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>LL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia</article-title>
<source/>Arch Gen Psychiatry
          <year>2006</year>
<volume>63</volume>
<fpage>630</fpage>
<lpage>638</lpage>
<pub-id pub-id-type="doi">10.1001/archpsyc.63.6.630</pub-id>
<pub-id pub-id-type="pmid">16754836</pub-id>
</element-citation>
</ref>
<ref id="CR63">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oomen</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Hvoslef-Eide</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Heath</surname>
<given-names>CJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The touchscreen operant platform for testing working memory and pattern separation in rats and mice</article-title>
<source/>Nat Protoc
          <year>2013</year>
<volume>8</volume>
<fpage>2006</fpage>
<lpage>2021</lpage>
<pub-id pub-id-type="doi">10.1038/nprot.2013.124</pub-id>
<pub-id pub-id-type="pmid">24051961</pub-id>
</element-citation>
</ref>
<ref id="CR64">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pagnamenta</surname>
<given-names>AT</given-names>
</name>
<name>
<surname>Wing</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Sadighi Akha</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A 15q13.3 microdeletion segregating with autism</article-title>
<source/>Eur J Hum Genet
          <year>2009</year>
<volume>17</volume>
<fpage>687</fpage>
<lpage>692</lpage>
<pub-id pub-id-type="doi">10.1038/ejhg.2008.228</pub-id>
<pub-id pub-id-type="pmid">19050728</pub-id>
</element-citation>
</ref>
<ref id="CR65">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paine</surname>
<given-names>TA</given-names>
</name>
<name>
<surname>Slipp</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Carlezon</surname>
<given-names>WA</given-names>
</name>
</person-group>
<article-title>Schizophrenia-like attentional deficits following blockade of prefrontal cortex GABAA receptors</article-title>
<source/>Neuropsychopharm
          <year>2011</year>
<volume>36</volume>
<fpage>1703</fpage>
<lpage>1713</lpage>
<pub-id pub-id-type="doi">10.1038/npp.2011.51</pub-id>
</element-citation>
</ref>
<ref id="CR66">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Passetti</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Chudasama</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Robbins</surname>
<given-names>TW</given-names>
</name>
</person-group>
<article-title>The frontal cortex of the rat and visual attentional performance: dissociable functions of distinct medial prefrontal subregions</article-title>
<source/>Cereb Cortex
          <year>2002</year>
<volume>12</volume>
<fpage>1254</fpage>
<lpage>1268</lpage>
<pub-id pub-id-type="doi">10.1093/cercor/12.12.1254</pub-id>
<pub-id pub-id-type="pmid">12427677</pub-id>
</element-citation>
</ref>
<ref id="CR67">
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Paxinos</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Franklin</surname>
<given-names>KBJ</given-names>
</name>
</person-group>
<source/>The mouse brain in stereotaxic coordinates
          <year>2008</year>
<publisher-loc>London</publisher-loc>
<publisher-name>Elsevier Academic Press</publisher-name>
</element-citation>
</ref>
<ref id="CR68">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pehrson</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Bondi</surname>
<given-names>CO</given-names>
</name>
<name>
<surname>Totah</surname>
<given-names>NKB</given-names>
</name>
<name>
<surname>Moghaddam</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>The influence of NMDA and GABA(A) receptors and glutamic acid decarboxylase (GAD) activity on attention</article-title>
<source/>Psychopharmacology
          <year>2013</year>
<volume>225</volume>
<fpage>31</fpage>
<lpage>39</lpage>
<pub-id pub-id-type="doi">10.1007/s00213-012-2792-z</pub-id>
<pub-id pub-id-type="pmid">22797703</pub-id>
</element-citation>
</ref>
<ref id="CR69">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pezze</surname>
<given-names>M</given-names>
</name>
<name>
<surname>McGarrity</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Mason</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Too little and too much: hypoactivation and disinhibition of medial prefrontal cortex cause attentional deficits</article-title>
<source/>J Neurosci
          <year>2014</year>
<volume>34</volume>
<fpage>7931</fpage>
<lpage>7946</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.3450-13.2014</pub-id>
<pub-id pub-id-type="pmid">24899715</pub-id>
</element-citation>
</ref>
<ref id="CR70">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Preskorn</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Gawryl</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Dgetluck</surname>
<given-names>N</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Normalizing effects of EVP-6124, an alpha-7 nicotinic partial agonist, on event-related potentials and cognition</article-title>
<source/>J Psychiatr Pract
          <year>2014</year>
<volume>20</volume>
<fpage>12</fpage>
<lpage>24</lpage>
<pub-id pub-id-type="doi">10.1097/01.pra.0000442935.15833.c5</pub-id>
<pub-id pub-id-type="pmid">24419307</pub-id>
</element-citation>
</ref>
<ref id="CR71">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Quian Quiroga</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>What is the real shape of extracellular spikes?</article-title>
<source/>J Neurosci Meth
          <year>2009</year>
<volume>177</volume>
<fpage>194</fpage>
<lpage>198</lpage>
<pub-id pub-id-type="doi">10.1016/j.jneumeth.2008.09.033</pub-id>
</element-citation>
</ref>
<ref id="CR72">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Robbins</surname>
<given-names>TW</given-names>
</name>
</person-group>
<article-title>The case of frontostriatal dysfunction in schizophrenia</article-title>
<source/>Schizophr Bull
          <year>1990</year>
<volume>16</volume>
<fpage>391</fpage>
<lpage>402</lpage>
<pub-id pub-id-type="doi">10.1093/schbul/16.3.391</pub-id>
<pub-id pub-id-type="pmid">2287930</pub-id>
</element-citation>
</ref>
<ref id="CR73">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Robbins</surname>
<given-names>TW</given-names>
</name>
</person-group>
<article-title>The 5-choice serial reaction time task: behavioural pharmacology and functional neurochemistry</article-title>
<source/>Psychopharmacology
          <year>2002</year>
<volume>163</volume>
<fpage>362</fpage>
<lpage>380</lpage>
<pub-id pub-id-type="doi">10.1007/s00213-002-1154-7</pub-id>
<pub-id pub-id-type="pmid">12373437</pub-id>
</element-citation>
</ref>
<ref id="CR74">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Romberg</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Mattson</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Mughal</surname>
<given-names>MR</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Impaired attention in the 3xTgAD mouse model of Alzheimer’s disease: rescue by donepezil (aricept)</article-title>
<source/>J Neurosci
          <year>2011</year>
<volume>31</volume>
<fpage>3500</fpage>
<lpage>3507</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.5242-10.2011</pub-id>
<pub-id pub-id-type="pmid">21368062</pub-id>
</element-citation>
</ref>
<ref id="CR75">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roxborough</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Muir</surname>
<given-names>WJ</given-names>
</name>
<name>
<surname>Blackwood</surname>
<given-names>DH</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Neuropsychological and P300 abnormalities in schizophrenics and their relatives</article-title>
<source/>Psychol Med
          <year>1993</year>
<volume>23</volume>
<fpage>305</fpage>
<lpage>314</lpage>
<pub-id pub-id-type="doi">10.1017/S0033291700028385</pub-id>
<pub-id pub-id-type="pmid">8332646</pub-id>
</element-citation>
</ref>
<ref id="CR76">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Snitz</surname>
<given-names>BE</given-names>
</name>
<name>
<surname>Macdonald</surname>
<given-names>AW</given-names>
</name>
<name>
<surname>Carter</surname>
<given-names>CS</given-names>
</name>
</person-group>
<article-title>Cognitive deficits in unaffected first-degree relatives of schizophrenia patients: a meta-analytic review of putative endophenotypes</article-title>
<source/>Schizophr Bull
          <year>2006</year>
<volume>32</volume>
<fpage>179</fpage>
<lpage>194</lpage>
<pub-id pub-id-type="doi">10.1093/schbul/sbi048</pub-id>
<pub-id pub-id-type="pmid">16166612</pub-id>
</element-citation>
</ref>
<ref id="CR77">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stefansson</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Meyer-Lindenberg</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Steinberg</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>CNVs conferring risk of autism or schizophrenia affect cognition in controls</article-title>
<source/>Nature
          <year>2014</year>
<volume>505</volume>
<fpage>361</fpage>
<lpage>366</lpage>
<pub-id pub-id-type="doi">10.1038/nature12818</pub-id>
<pub-id pub-id-type="pmid">24352232</pub-id>
</element-citation>
</ref>
<ref id="CR78">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Steward</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Tomasulo</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Levy</surname>
<given-names>WB</given-names>
</name>
</person-group>
<article-title>Blockade of inhibition in a pathway with dual excitatory and inhibitory action unmasks a capability for LTP that is otherwise not expressed</article-title>
<source/>Brain Res
          <year>1990</year>
<volume>516</volume>
<fpage>292</fpage>
<lpage>300</lpage>
<pub-id pub-id-type="doi">10.1016/0006-8993(90)90930-A</pub-id>
<pub-id pub-id-type="pmid">2364294</pub-id>
</element-citation>
</ref>
<ref id="CR79">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stocker</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Krause</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pedarzani</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>An apamin-sensitive Ca2+-activated K+ current in hippocampal pyramidal neurons</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>1999</year>
<volume>96</volume>
<fpage>4662</fpage>
<lpage>4667</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.96.8.4662</pub-id>
<pub-id pub-id-type="pmid">10200319</pub-id>
</element-citation>
</ref>
<ref id="CR80">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tepper</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>LP</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>DR</given-names>
</name>
</person-group>
<article-title>GABAA receptor-mediated inhibition of rat substantia nigra dopaminergic neurons by pars reticulata projection neurons</article-title>
<source/>J Neurosci
          <year>1995</year>
<volume>15</volume>
<fpage>3092</fpage>
<lpage>3103</lpage>
<pub-id pub-id-type="pmid">7722648</pub-id>
</element-citation>
</ref>
<ref id="CR81">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Totah</surname>
<given-names>NKB</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>YB</given-names>
</name>
<name>
<surname>Homayoun</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Moghaddam</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Anterior cingulate neurons represent errors and preparatory attention within the same behavioral sequence</article-title>
<source/>J Neurosci
          <year>2009</year>
<volume>29</volume>
<fpage>6418</fpage>
<lpage>6426</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.1142-09.2009</pub-id>
<pub-id pub-id-type="pmid">19458213</pub-id>
</element-citation>
</ref>
<ref id="CR82">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tse</surname>
<given-names>MT</given-names>
</name>
<name>
<surname>Piantadosi</surname>
<given-names>PT</given-names>
</name>
<name>
<surname>Floresco</surname>
<given-names>SB</given-names>
</name>
</person-group>
<article-title>Prefrontal cortical gamma-aminobutyric acid transmission and cognitive function: drawing links to schizophrenia from preclinical research</article-title>
<source/>Biol Psychiat
          <year>2015</year>
<volume>77</volume>
<fpage>929</fpage>
<lpage>939</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2014.09.007</pub-id>
<pub-id pub-id-type="pmid">25442792</pub-id>
</element-citation>
</ref>
<ref id="CR83">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tseng</surname>
<given-names>KY</given-names>
</name>
<name>
<surname>Lewis</surname>
<given-names>BL</given-names>
</name>
<name>
<surname>Hashimoto</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A neonatal ventral hippocampal lesion causes functional deficits in adult prefrontal cortical interneurons</article-title>
<source/>J Neurosci
          <year>2008</year>
<volume>28</volume>
<fpage>12691</fpage>
<lpage>12699</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.4166-08.2008</pub-id>
<pub-id pub-id-type="pmid">19036962</pub-id>
</element-citation>
</ref>
<ref id="CR84">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Umbricht</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Keefe</surname>
<given-names>RSE</given-names>
</name>
<name>
<surname>Murray</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A randomized, placebo-controlled study investigating the nicotinic α7 agonist, RG3487, for cognitive deficits in schizophrenia</article-title>
<source/>Neuropsychopharmacol
          <year>2014</year>
<volume>39</volume>
<fpage>1568</fpage>
<lpage>1577</lpage>
<pub-id pub-id-type="doi">10.1038/npp.2014.17</pub-id>
</element-citation>
</ref>
<ref id="CR85">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Volk</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Austin</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Pierri</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>GABA transporter-1 mRNA in the prefrontal cortex in schizophrenia: decreased expression in a subset of neurons</article-title>
<source/>Am J Psychiat
          <year>2001</year>
<volume>158</volume>
<fpage>256</fpage>
<lpage>265</lpage>
<pub-id pub-id-type="doi">10.1176/appi.ajp.158.2.256</pub-id>
<pub-id pub-id-type="pmid">11156808</pub-id>
</element-citation>
</ref>
<ref id="CR86">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weisbrod</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hill</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Niethammer</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Sauer</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Genetic influence on auditory information processing in schizophrenia: P300 in monozygotic twins</article-title>
<source/>Biol Psychiat
          <year>1999</year>
<volume>46</volume>
<fpage>721</fpage>
<lpage>725</lpage>
<pub-id pub-id-type="doi">10.1016/S0006-3223(99)00022-0</pub-id>
<pub-id pub-id-type="pmid">10472425</pub-id>
</element-citation>
</ref>
<ref id="CR87">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Winters</surname>
<given-names>BD</given-names>
</name>
<name>
<surname>Saksida</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Bussey</surname>
<given-names>TJ</given-names>
</name>
</person-group>
<article-title>Object recognition memory: neurobiological mechanisms of encoding, consolidation and retrieval</article-title>
<source/>Neurosci Biobehav Rev
          <year>2008</year>
<volume>32</volume>
<fpage>1055</fpage>
<lpage>1070</lpage>
<pub-id pub-id-type="doi">10.1016/j.neubiorev.2008.04.004</pub-id>
<pub-id pub-id-type="pmid">18499253</pub-id>
</element-citation>
</ref>
<ref id="CR88">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wobrock</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kadovic</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Reduced cortical inhibition in first-episode schizophrenia</article-title>
<source/>Schizophrn Res
          <year>2008</year>
<volume>105</volume>
<fpage>252</fpage>
<lpage>261</lpage>
<pub-id pub-id-type="doi">10.1016/j.schres.2008.06.001</pub-id>
</element-citation>
</ref>
<ref id="CR89">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Young</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Finlayson</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Spratt</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Nicotine improves sustained attention in mice: evidence for involvement of the α7 nicotinic acetylcholine receptor</article-title>
<source/>Neuropsychopharmacol
          <year>2004</year>
<volume>29</volume>
<fpage>891</fpage>
<lpage>900</lpage>
<pub-id pub-id-type="doi">10.1038/sj.npp.1300393</pub-id>
</element-citation>
</ref>
<ref id="CR90">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Young</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Crawford</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Kelly</surname>
<given-names>JS</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Impaired attention is central to the cognitive deficits observed in alpha 7 deficient mice</article-title>
<source/>Eur Neuropsychopharm
          <year>2007</year>
<volume>17</volume>
<fpage>145</fpage>
<lpage>155</lpage>
<pub-id pub-id-type="doi">10.1016/j.euroneuro.2006.03.008</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>